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IRHZ – incidence rate of herpes zoster 
IVHet - fixed-effect inverse variance heterogeneity model 
JC – jaw claudication 
ln – natural logarithm  
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MRI – magnetic resonance imaging 
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NLR – negative likelihood ratio 
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R2 – McFaddens pseudo-R squared for logistic regression 
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Risk – the probability of an event or outcome 
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SJR – SCImago Journal Rank (higher SJR score indicates greater journal prestige) 
P-LR – Primary Logistic Regression model (n=530) 
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SVM – support vector machines 
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TABx – temporal artery biopsy 
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VL – vision loss attributable to ischemia 
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PREFACE 
 
Figure 1. “Temporary” artery biopsy malapropism 
 
The title of this 1989 study from New Zealand (Stuart, 1989) has a malapropism encircled in 
red.  Instead of “temporal” the title lists “temporary”.  Paradoxically the malapropism 
appropriately conveys the desire of patients and clinicians to have a non-invasive but accurate 
method to confirm the pathologic diagnosis of giant cell arteritis, without leaving a permanent 
scar.    
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ABSTRACT 
     Giant cell arteritis (GCA) is the most common primary vasculitis in the elderly and can 
cause irreversible blindness, aortitis, and stroke.   Diagnostic confirmation of GCA usually 
entails temporal artery biopsy (TABx) – a time-consuming and invasive test, or ultrasound.  
The primary treatment of GCA is with high dose glucocorticoids that have numerous 
potential side effects.  Glucocorticoids are initiated prior to the TABx result, due to the risk 
of interim blindness. By 2050 the cost of blindness from GCA in the United States is 
estimated at $76 billion with an additional $6 billion from glucocorticoid-induced fractures. 
     This thesis examines knowledge gaps in the diagnosis and epidemiology of GCA.  
Needed refinements in the diagnosis of GCA included:  i) the optimization of diagnostic 
prediction models (PMs) and ii) clarification of the contemporary utilization parameters of 
TABx.  With regards to i) previous PMs are usually based on limited sample size, do not 
leverage sufficient clinical predictors, or include continuous variables, and not compliant 
with the transparent reporting guidelines for diagnostic PMs (TRIPOD).  Using multicentre 
data of consecutive patients undergoing TABx, the largest (n=1,201) and most 
comprehensive logistic regression and, neural network PMs for GCA were formulated.  Age, 
platelet level, jaw claudication and vision loss eventuated as the key predictor variables. An 
online risk calculator was developed from the PM and could decrease both the number of 
TABx performed on low-risk patients, and the morbidity from unneeded glucocorticoids.   
Regarding ii) although TABx has long been acknowledged as the gold standard test for GCA 
the current preference for TABx versus ultrasound amongst neuro-ophthalmologists and the 
utility rate of TABx are unknown.  The thesis survey revealed that 91% of neuro-
ophthalmologists preferred TABx over ultrasound as the confirmatory test for GCA. The first 
systematic review for the utility rate of TABx disclosed a median positive yield of 25% and 
provides a benchmark for institutions performing this procedure. 
     Knowledge gaps in the epidemiology of GCA important for public health planning 
included the incidence of GCA in Ontario, Canada, and the controversial role of herpes zoster 
in the development of GCA given the advent of zoster vaccines.  Pathology audit and an 
assay of billing data revealed the incidence of biopsy-proven GCA in Ontario to be 4.9 per 
100,000 individuals 50 years of age or older.  On ecologic analysis, the inverse relationship 
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of the incidence rates of herpes zoster versus GCA per country suggested zoster is not a 
major immunopathogenic trigger for GCA. 
     In summary, this thesis advances the diagnosis and epidemiology of GCA, most notably in 
the area of clinical prediction models that aid in the triage of patients with suspected GCA. 
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Chapter 1.  INTRODUCTION 
     Giant cell arteritis (GCA) is the most common primary vasculitis in adults.  This 
autoimmune inflammation of the arteries can cause ischemia from luminal stenosis, with the 
potential for irreversible blindness, aortitis, myocardial infarction, stroke and occasionally 
death. It is a disease of immunosenescence that almost always occurs after the age of 50 years.  
GCA is a prime emergency in ophthalmology (Torun and Ing, 2008; Danesh-Meyer, 2012; 
Waldman, Waldman and Waldman, 2013) and by the year 2050, the projected cost of GCA 
from visual impairment in the United States alone is estimated to be US$76 billion, with an 
additional $US6 billion from glucocorticoid-induced fractures (De Smit, Palmer and Hewitt, 
2015).  
       The thesis publications focus on the diagnosis and epidemiology of GCA.   Knowledge 
gaps in the diagnosis of GCA were suboptimal diagnostic prediction models (PMs) and the 
contemporary utilization parameters of temporal artery biopsy (TABx) - the traditional “gold 
standard” confirmatory test for GCA.  Prior PMs were undersized, did not leverage 10 
clinical predictors or include continuous variables, (Cumberland et al., 2014), and were 
noncompliant with the rigour of guidelines for the transparent reporting of multivariable 
prediction models for individual diagnosis (TRIPOD) (Collins et al., 2015).  Although TABx 
has long been acknowledged as the reference standard confirmatory test for GCA, the 
positive yield of TABx in pathology series and the current work-up preference of TABx 
versus Doppler ultrasound amongst neuro-ophthalmologists were unknown.  GCA can be 
difficult to identify, and two conditions that mimic or overlap with GCA are also briefly 
discussed in the diagnosis section. 
     Salient topics in the epidemiology of GCA important for public health planning, were the 
incidence of GCA in Ontario, Canada, and the contentious role of herpes zoster in the 
development of GCA.  The province of Ontario houses one-third of Canada’s population, but 
the incidence of GCA in this locale had not been previously researched.  To determine if 
there was a biologic gradient between herpes zoster and GCA, a novel ecologic analysis was 
performed comparing the published incidence rates of zoster versus GCA from different 
countries. The relationship between zoster and GCA is important to clarify especially given 
the advent of the zoster vaccines.  The coherence of the publications on the diagnosis and 
epidemiology of GCA is illustrated in Figure 3. 
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1.1  The Immunology and Pathology of GCA 
 
     This thesis does not investigate the complex immunopathology of GCA, but the same is 
reviewed to provide context on this critical field of study.  Immune checkpoints are molecules 
on immune cells that need to be activated or inactivated to start an immune response.  
Inefficiency of the PD-1 / PD-L1 (programmed cell death protein 1 / programmed death-
ligand 1) immune checkpoint has been recently described in GCA, and implicated in other eye 
diseases including uveal melanoma and uveitis (Wang et al., 2019).  Programmed cell death 
protein 1 (PD-1) is a co-inhibitory receptor expressed on T-cells and delivers negative signals 
when engaged by its immunoinhibitory ligand PD-L1 which is located in the vascular 
dendritic cell.  After binding with PD-L1, PD-1 normally acts like an “off-switch” and 
restrains T-cells from attacking.  With GCA the vascular dendritic cells have a low expression 
of PD-L1 and the tissue-invading T-cells are unrestrained.    
     Vascular dendritic cells are the immune sentinels of the blood vessel and reside at the 
junction of the outer and middle layer of the blood vessel (adventitia-media border).  In GCA, 
the dendritic cells become activated by an unknown trigger(s) possibly via toll-like receptors1 
(transmembrane pattern-recognition receptors on the dendritic cell that sense pathogens or 
signals of endogenous damage) resulting in the production of cytokines and chemokines 
(signalling proteins that attract white blood cells) (Weyand, Liao and Goronzy, 2012; 
Terrades-Garcia and Cid, 2018). Failure of the activated vascular dendritic cells to express the 
immunoinhibitory ligand PD-L1 within an aged arterial wall leaves the PD-1 positive CD4 T-
cells insufficiently suppressed that in turn contribute to macrophage activation and further 
excessive production of pro-inflammatory cytokines.  The latter polarize the CD4 T cells 
toward T-helper 1 (Th1) and T-helper 17 (Th17) differentiation.  Th1 cells produce interferon-
gamma, a potent activator of macrophages that can damage the vessel wall.   The interleukin 6 
(IL-6) cytokine is a pivotal driver for the polarization of CD4 T cells toward the Th17 
phenotype that in turn produce interleukin-17 which is involved in the development of the 
systemic inflammatory symptoms of GCA.  Glucocorticoids and tocilizumab can decrease the 
activation of Th17 cells, and thereby the production of IL17, but do not alter the Th1 pathway. 
(Mohan et al., 2011; Weyand, Berry and Goronzy, 2018)   
 
1 Toll-like receptors (TLRs) are a key player in the innate immune system. The designation TLRs is due its 
resemblance to a protein from the Drosophila toll gene. 
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     Histologic specimens to test for the diagnosis of GCA usually are obtained from the 
temporal artery.  The pathology of GCA characteristically shows granulomatous inflammation 
in the arterial wall with histiocytes (activated macrophages), epithelioid cells (epithelioid 
histiocytes) and/or abnormally large multinucleated epithelioid cells with the appellation of 
“giant cells”.  Although atherosclerosis may also show intimal thickening, typical GCA 
displays active mural inflammation.2 
 
 
1.2 GCA:  Clinical Background 
 
     The diagnosis of GCA can be difficult and often is delayed because GCA can present in a 
protean fashion, with non-specific symptoms, (Prior et al., 2017) and has no highly-specific 
serologic biomarker (De Smit et al., 2016).  There are three main subtypes of GCA that can 
phenotypically overlap:  1) cranial arteritis with propensity for vision loss and cerebral 
ischemia; 2) large vessel vasculitis (aortic arch syndrome, aortitis); and 3) polymyalgia 
rheumatica. (Dejaco et al., 2017)  The symptoms and signs of GCA can mimic other diseases 
such as infection, malignancy, amyloidosis (Ing et al., 1997), or other vasculitides (Ong Tone, 
Godra and Ing, 2013), sinusitis, idiopathic orbital inflammatory syndrome (Islam et al., 2003), 
dental or temporo-mandibular conditions, non-arteritic ischemic optic neuropathy, and 
atherosclerotic disease.   
     Medical students and physicians are taught universally to suspect GCA in any older patient 
who develops headache, vision loss or diplopia.  Notwithstanding, some GCA patients still 
develop vision loss from undiagnosed ocular ischemia, especially if the disease presents in an 
occult (Hayreh, Podhajsky and Zimmerman, 1998)(Husain et al., 2008) or atypical manner.  
Occasionally, despite the expedient diagnosis and immediate treatment with maximal 
intravenous steroids patients with cranial GCA may succumb to progressive, irreversible 
ischemic blindness from GCA that can sequentially involve both eyes, or rarely be bilateral 
(Loddenkemper et al., 2007).   
      
     At the start of the period during which this thesis was undertaken, the main guidance to 
assist in the identification of GCA was the 1990 American College of Rheumatology (ACR) 
 
2 See section 4.1.1 page 55 for a discussion on the pathology of healed arteritis. 
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classification criteria.3 (Hunder et al., 1990)  However, the ACR classification criteria were 
developed for research purposes to differentiate GCA from patients with other forms of 
vasculitis, rather than for the diagnosis of individual patients who might have other non-
vasculitic diseases that mimic the presentation of GCA (Hunder, 1998).  The ACR criteria 
misidentify many ophthalmic cases of GCA with 26% false negatives and 28% false positives.  
(Murchison et al., 2012).      
     According to the Swedish Society of Rheumatology 2018 guidelines (Turesson et al., 
2019) and other authorities,(Danesh-Meyer, 2012; Ness et al., 2013; Banerjee, Petrou and 
Plant, 2014; Weyand and Goronzy, 2014; Frohman et al., 2016; Koster and Warrington, 2017) 
temporal artery biopsy (TABx) remains the “gold” standard confirmatory test for GCA.    
However, TABx is an invasive, somewhat time-consuming test that can be difficult to obtain 
in a prompt fashion at some centres.  Complications of TABx are uncommon, but include 
hematoma, wound dehiscence, scarring, infection and rarely facial nerve palsy, scalp necrosis, 
and very rarely cerebral ischemia if the temporal artery is a critical collateral to the brain 
circulation.  The sensitivity of TABx is between 77% (Rubenstein et al., 2019) and 87%, 
(Niederkohr and Levin, 2007) but there may be false negatives when the vasculitis is 
segmental and the specimen does not sample an affected area.  The permanent section 
pathology result from TABx usually requires days or even a week to obtain.  Given the above, 
the European League Against Rheumatism guidelines (Dejaco et al., 2018) suggest ultrasound 
and high-resolution MRI as an alternative to TABx at centres with sufficient expertise in 
conducting these studies.   
     Unfortunately, there is no consensus on the sensitivity of ultrasound for GCA.   One meta-
analysis of ultrasound for clinically diagnosed GCA suggests a sensitivity of 77% (95% CI: 
62%-87%) (Duftner et al., 2018), but a larger meta-analysis from the same time period found 
the sensitivity was 68% (95% CI: 57%-78%) (Rinagel et al., 2019).  The sensitivity of MRI 
for GCA may be 73% (95% CI: 57-85%) (Duftner et al., 2018).  In comparison the sensitivity 
of TABx for GCA varies from 77% (95% CI: 72%-82%) on meta-analysis (Rubenstein et al., 
2019) to 87% (95% CI: 82%-92%) on Bayesian analysis (Niederkohr and Levin, 2007).   
     The mainstay treatment for GCA is prolonged glucocorticoids which have many potential 
side effects including glucocorticoid-induced fractures, bone loss, diabetes mellitus, 
 
3 The 1990 ACR classification criteria for GCA are: age >=50 years of age, new onset localized headache, 
temporal artery tenderness to palpation or decreased pulsation, erythrocyte sedimentation rate >=50 mm/hour, 
and positive temporal artery biopsy.   
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pneumonia, cataract, glaucoma, (Broder et al., 2016) hypertension and peptic ulcers.  Due to 
the risk of vision loss, if GCA is suspected, steroids are initiated prophylactically prior to 
TABx. Adjunctive treatment with the IL-6 receptor inhibitor, tocilizumab is a recent 
development. (Stone et al., 2017) (Sadun and Gordon, 2020) 
          Due to the potential for irreversible vision loss, and the side-effects of glucocorticoids, 
GCA is a high stakes diagnosis.  My motivation for pursuing research in GCA is that it is one 
of the most-anxiety provoking diseases in my ophthalmology practice.  Over the last 30 years, 
I have encountered many apprehensive, elderly patients with clinical or bloodwork 
abnormalities suspicious for GCA, who cannot decide whether to undergo TABx, start  
glucocorticoids, or continue on their prescribed glucocorticoids without a tissue diagnosis.  
Both patients and physicians wish that TABx could be less invasive,  (See Figure 1) and 
avoided if patients can be determined to be at low risk.  To clarify, “risk” in this thesis refers 
to the probability of occurrence of an event or outcome (Ranganathan, Aggarwal and Pramesh, 
2015).  
     Artificial intelligence and actuarial models are usually superior to clinical intuition for 
medical diagnosis (Meehl, 1954; Ayres, 2007; The Medical Futurist, 2016; Mukherjee, 2017).  
The diagnosis of GCA by clinical intuition alone is prone to bias because humans in 
comparison with statistical models cannot objectively or accurately weigh the multiple risk 
factors for GCA, especially those with a non-linear profile (See  
 
Figure 8).  Actuarial classification algorithms can provide an objective risk assessment that 
aids medical decision-making, and potentially allow physicians to deliver better care (Bower, 
2018; Parikh, 2018).  Furthermore, a risk calculator for GCA may help avoid TABx in patients 
deemed at low risk for GCA.   
     This thesis also explored the epidemiology of GCA with respect to the incidence of GCA in 
Ontario, Canada, and the role of herpes zoster in GCA.  Although Ontario is the most 
populous province in Canada, no prior incidence study had been performed.  To examine the 
relationship between herpes zoster and GCA, we published the first ecologic analysis 
comparing the incidence rates of both conditions in different countries. 
     In summary, my thesis addresses challenges in the epidemiology and diagnosis of GCA.  
Knowledge gaps in the epidemiology of GCA important for public health planning included 
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the incidence of GCA in Ontario, Canada, and the controversial role of herpes zoster in the 
development of GCA given the advent of the zoster vaccines.     
     Needed refinements in the diagnosis of GCA included the clarification of the 
contemporary utilization parameters of temporal artery biopsy (TABx), and optimization of 
diagnostic prediction models (PMs).   
     The most significant, original contribution of the publications in this thesis are the PMs 
that stratify a patient’s risk of GCA prior to TABx.  PMs with more than one predictor 
variable i.e. multivariable PMs were developed using three different classification 
algorithms:  logistic regression, support vector machine and neural networks.  Logistic 
regression is one of the most used classification algorithms in medicine and was chosen over 
linear regression / polynomial (quadratic) regression because the outcome of our PMs is 
binary i.e. negative TABx versus positive TABx.   (see the Methodology Section 4.1)  Each 
algorithm was examined to determine if misclassification errors particularly false-negative 
errors could be minimized as a missed opportunity to prevent potential blindness is one the 
costliest errors in GCA.  The PMs are intended to allay patient angst, support patient-doctor 
collaborative decision-making, and provide a pretest probability for GCA that allows 
clinicians to adjudicate better between observation versus investigative options, and to 
determine if glucocorticoid treatment or other treatment is appropriate. 
 
 
 
Figure 2. Précis of the major contribution of this thesis 
 
 
 
The multivariable diagnostic prediction models in this thesis risk stratify patients with 
suspected giant cell arteritis (GCA) prior to temporal artery biopsy.  Increasing age and 
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platelet levels, and the presence of jaw claudication, and vision loss were found to be the 
strongest predictors of GCA.  
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Chapter 2.  THESIS PUBLICATIONS  
Figure 3. Pictorial Summary of Thesis Publications 
 
 
DIAGNOSIS:  Statistical Prediction Models  
 
1. a) Multivariable prediction model for suspected giant cell arteritis: development and 
validation.  Ing EB, Lahaie Luna G, Toren A, Ing R, Chen JJ, Arora N, Torun N, Jakpor OA, 
Fraser JA, Tyndel FJ, Sundaram AN, Liu X, Lam CT, Patel V, Weis E, Jordan D, Gilberg S, 
Pagnoux C, Ten Hove M.  Clin Ophthalmol. 2017 Nov 22;11:2031-2042. 
 
1. b) The Use of a Nomogram to Visually Interpret a Logistic Regression Prediction Model for 
Giant Cell Arteritis. Ing EB, Ing R.  Neuroophthalmology. 2018 Feb 5;42(5):284-286.  
 
1. c) Aids to statistics literacy for ophthalmologists. Ing E. Can J Ophthalmol. 2016 
Oct;51(5):e142-e143. 
 
2.  Support Vector Machines and logistic regression to predict temporal artery biopsy 
outcomes.  Ing E, Su W, Schonlau M, Torun N.  Can J Ophthalmol. 2019 Feb;54(1):116-118.   
 
3.  Neural network and logistic regression diagnostic prediction models for giant cell arteritis: 
development and validation.  Ing EB, Miller NR, Nguyen A, Su W, Bursztyn LLCD, Poole 
M, Kansal V, Toren A, Albreki D, Mouhanna JG, Muladzanov A, Bernier M, Gans M, Lee D, 
Wendel C, Sheldon C, Shields M, Bellan L, Lee-Wing M, Mohadjer Y, Nijhawan N, Tyndel 
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F, Sundaram ANE, Ten Hove MW, Chen JJ, Rodriguez AR, Hu A, Khalidi N, Ing R, Wong 
SWK, Torun N.  Clin Ophthalmol. 2019 Feb 21;13:421-430. 
 
DIAGNOSIS:  Temporal Artery Biopsy:  Utility rate, Technique, Practice Preferences  
 
4. a) Systematic Review of the Yield of Temporal Artery Biopsy for Suspected Giant Cell 
Arteritis.  Ing EB, Wang DN, Kirubarajan A, Benard-Seguin E, Ma J, Farmer JP, Belliveau 
MJ, Sholohov G, Torun N.  Neuroophthalmology. 2018 Jun 19;43(1):18-25. 
 
4. b) Local anaesthesia and anxiolytic techniques for oculoplastic surgery.  Ing EB, Philteos J, 
Sholohov G, Kim DT, Nijhawan N, Mark PW, Gilbert J.  Clin Ophthalmol. 2019 Jan 
10;13:153-160. 
 
4. c) New oral anticoagulants and oculoplastic surgery. Ing E, Douketis J. Can J Ophthalmol. 
2014 Apr;49(2):123-7. 
 
5.  Practice Preferences: Temporal Artery Biopsy versus Doppler Ultrasound in the Work-up of Giant 
Cell Arteritis.  Ing E, Xu Q, Chuo J, Kherani F, Landau K. Accepted by Neuro-Ophthalmology, Aug 
13, 2019. 
 
 
DIAGNOSIS:  Differential Diagnosis:  
 
6. a)  Polyangiitis overlap syndrome with granulomatosis with polyangiitis (Wegener's) and 
giant cell arteritis.  Ong Tone S, Godra A, Ing E.  Can J Ophthalmol. 2013 Feb;48(1):e6-8.  
 
6. b)  Systemic amyloidosis with temporal artery involvement mimicking temporal arteritis.   
Ing EB, Woolf IZ, Younge BR, Bjornsson J, Leavitt JA.  Ophthalmic Surg Lasers. 1997 
Apr;28(4):328-31. 
 
Epidemiology:  
 
7.  The incidence of giant cell arteritis in Ontario, Canada.  Ing EB, Lahaie Luna G, Pagnoux 
C, Baer PA, Wang D, Benard-Seguin E, Godra I, Godra A, Munoz DG, McReelis K, Ten 
Hove M. Can J Ophthalmol. 2019 Feb;54(1):119-124.  
 
8.  Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study.  Ing EB, 
Ing R, Liu X, Zhang A, Torun N, Sey M, Pagnoux C.  Clin Ophthalmol. 2018 Jan 11;12:113-
118.  
 
 
Impact:  Critiques of GCA Literature  
 
9. a)  Bloodwork statistical prediction model for giant cell arteritis.  Ing E. Intern Med J. 2018 
May;48(5):607-608. (Comments on:  Full blood count as an ancillary test to support the 
diagnosis of giant cell arteritis. [Intern Med J. 2018]) 
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9. b)  Comments on the giant cell arteritis probability score (Laskou’s model). Ing E, Sambhi 
G, Torun N, Pagnoux C.  Clin Exp Rheumatol. 2019 Mar-Apr;37 Suppl 117(2):150. Epub 
2019 May 8.   Clin Exp Rheumatol  (Comment on: Laskou F et al.  A probability score to aid 
the diagnosis of suspected giant cell arteritis.  Clin Exp Rheumatol. 2019 37 Suppl 117(2): 
104-108.) 
 
9. c) Ing E.  Letter to the Editor.  Neural network and logistic regression predictive calculator 
for giant cell arteritis.  Arch Soc Esp Oftalmol. 2019 Sep 5. pii: S0365-6691(19)30235-7. doi: 
10.1016/j.oftal.2019.07.011. [Epub ahead of print] English, Spanish.    (Comments on Moraña 
MN, Sevillano C, Martínez S, Carral ML. Giant cell arteritis and usefulness of a predictive 
calculator.)   
 
9. d)  Ing E, Miller N, ten Hove M, Torun N.  Letter to the Editor.  Diplopia and giant cell 
arteritis: Response. J Neuroophthalmol. 2019 Sep 5. doi: 10.1097/WNO.0000000000000847. 
[Epub ahead of print] (Comments on Ross, Ahmara G.; Jivraj, Imran; Rodriguez, 
Geoffrey; More et al.  Retrospective, Multicenter Comparison of the Clinical Presentation of 
Patients Presenting with Diplopia from Giant Cell Arteritis vs Other Causes.   J Neuro-
Ophthalmology. 39(1):8-13, March 2019. 
9. e)  Ing E.   Comment on: “A new era for giant cell arteritis”, Eye, (Lond), online ahead of 
print Nov 25, 2019. (Comments on Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. 
A new era for giant cell arteritis’.  Eye (Lond).  2019 Oct 3, online ahead of print) 
 
10.  Ing E, Pagnoux C, Torun N.  Advances in the diagnosis of giant cell arteritis..  Curr Opin 
Ophthalmol, 2019 Sep 9.  doi: 10.1097/ICU.0000000000000616. [Epub ahead of print] 
 
 
Cross-Cutting Publications:    
 
Ing E.  Neuro-ophthalmic History, Ophthalmology emedicine chapter, peer-reviewed,  
annually updated Nov 2018, accessed Nov 26, 2018.  
https://emedicine.medscape.com/article/1832674-overview#showall 
 
Ing E.  Neuro-ophthalmic Physical examination, Ophthalmology emedicine chapter, peer 
reviewed, updated Jul 2019, accessed Jul 1, 2019.  
https://emedicine.medscape.com/article/1820707-overview#showall 
 
The next section of the thesis will present the research undertaken, providing a summary of 
each study and key findings.  The first nine papers focus on the diagnosis of GCA, followed 
by two studies on the epidemiology of GCA. 
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2.1 Diagnosis of GCA and Prediction Models 
2.1.1  Multivariable logistic regression prediction model for suspected GCA: development and 
validation. Clinical Ophthalmology, 2017      
 
     Based on clinical experience, a review of the literature, and a pilot study of ocular pulse 
amplitude in patients undergoing TABx (Ing, Pagnoux, et al., 2018) I a priori selected for the 
logistic regression model the predictors:  age, gender, new-onset headache, temporal artery 
tenderness or pulselessness, jaw claudication, vision loss, diplopia, Westergren erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP) and platelet level.4  All these variables, 
including platelets (Price and Clearkin, 1994) are information commonly collected from 
patients with suspected GCA.  Chart review by myself and collaborators at multiple centres 
was performed on consecutive patients who underwent a TABx for suspected GCA.  Patients 
using systemic glucocorticoids for more than 2 weeks were excluded from the study, because 
glucocorticoids can obscure the pathologic findings of GCA.   
     On multivariable logistic regression (LR) with external validation, this primary model 
(n=530) found that the platelet level, age, jaw claudication, vision loss, log CRP, new-onset 
headache and, temporal artery abnormality were statistically significant predictors of GCA, 
but the log ESR, gender, and diplopia were not.  
     In comparison with other LR models in the literature listed in Table 1, (Gabriel et al., 1995; 
Rodriguez-Valverde et al., 1997; Rieck et al., 2011; González-López et al., 2013; De Lott and 
Burke, 2015; El-Dairi et al., 2015; Grossman et al., 2016; Weis et al., 2017; Oh, Wong, 
Andrici, et al., 2018) the prediction models described in this thesis are the largest in the 
literature, had sufficient GCA events to support the 10 a priori predictors, increased statistical 
power by maintaining age and bloodwork predictors as continuous variables, one of the few 
rules to consider CRP, and are the only models with external validation and compliance with 
the rigorous transparent guidelines for the reporting of prediction models (TRIPOD) from the 
EQUATOR network (Collins et al., 2015).  Unlike some other models, (De Lott and Burke, 
2015; Weis et al., 2017; Oh, Wong, Andrici, et al., 2018) the thesis models utilize symptoms 
and signs as well as bloodwork values.  Only one other model has an associated spreadsheet 
risk calculator, (González-López et al., 2014) but it is not useful for a pre-biopsy risk 
calculation as it requires input of the length of the TABx (Ing, 2019b; Moraña et al., 2019).  
 
4 Polymyalgia rheumatica was not chosen as a predictor variable for the four reasons listed on page 56, section 
4.1.1. 
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Also, the Gonzalez-Lopez calculator is not publicly available, and must be requested from the 
author. 
 
  
Table 1. Review of the Logistic Regression Prediction Models for GCA in the Literature  
Author 
(Year) 
N [complete case analysis] 
(positive biopsy events) 
Statistically Significant Predictors Odds 
Ratio 
Gabriel 
(1995) 
525 
(172) 
All claudication 
Synovitis 
TAabn 
Highest ESR 
4.55 
0.31 
2.55 
1.01 
Rodriguez-Valverde, 
(1997) 
227 
(90) 
New headache 
TAabn 
Jaw claudication 
Raised liver enzymes 
< 70 years old at disease onset 
13.6 
4.2 
4.8 
2.9 
0.11 
Rieck 
(2011) 
82 
(22) 
Jaw claudication 
Weight loss 
4.50 
3.76 
Gonzalez-Lopez 
(2013) 
335 
(81) 
Jaw claudication 
New headache 
TAabn 
Pain and stiffness in neck and       
 shoulders 
Unintentional weight loss 
Age 
Biopsy Length 
ESR 
4.6 
4.4 
2.8 
2.3 
 
1.33 
1.085 
1.079 
1.042 
De Lott  
(2015)  
239 
(?90) 
Age 
Platelets 
1.06 
1.01 
El-Dairi  
(2015) 
213 
(61) 
Age > 65 years 
White 
Jaw claudication 
CRP > 0.5 mg/dL 
Platelets > 400K/µL 
4.28 
6.59 
3.45 
2.6 
3.2 
Grossman 
(2016) 
224 
(57) 
[25 biopsy negative GCA cases 
were included] 
New headache 
Jaw claudication 
ESR 
Platelets 
6.0 
4.5 
1.5 
1.74 
Weis 
(2017) 
119 
(29) 
ESR 
Platelets 
(Jaw claudication) 
1.03 
1.01 
(4.81) 
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Ing 
(2017) 
530 
(133) 
Age 
Jaw Claudication 
Vision Loss 
Platelets 
LogCRP 
1.04 
4.0 
2.7 
1.005 
1.35  
Oh 
(2018) 
347 
(79) 
Platelets  
ESR 
3.187 
2.005 
Ing 
(2019) 
1,201* 
(300) 
Age 
Headache 
TAabn 
Jaw claudication 
Vision loss 
LogESR 
LogCRP 
Platelets 
1.060 
1.540 
1.466 
3.398 
2.611 
1.200 
1.370  
1.005 
GCA = giant cell arteritis; TAabn = temporal artery abnormality on physical exam 
*In this series which is discussed extensively later in the thesis a total of 1,833 subjects underwent TABx; 1, 201 
had complete information for logistic regression analysis. 
 
     The primary logistic regression (P-LR) model (n=530) had a good area under the receiving 
operating characteristic (AUROC) of 0.81 on bootstrap cross validation, which was sustained 
on serial geographic external validation with AUROC 0.75-0.85.  The P-LR model handily 
outperformed the 1990 American College of Rheumatology (ACR) classification criteria for 
GCA (Hunder et al., 1990).  Although the ACR classification criteria were never meant for the 
diagnosis of individual patients with GCA, (Hunder, 1998) numerous articles have attempted 
to repurpose them (Davies and May, 2011; Quinn et al., 2012; Pieri et al., 2013; Cristaudo, 
Mizumoto and Hendahewa, 2016; Hussain et al., 2016).  The P-LR model was a better 
discriminator for the diagnosis of GCA than the 1990 ACR classification criteria. 
 
 
 
Figure 4. Discrimination of the Full and Parsimonious Primary Logistic Regression Model 
(published in 2017; n=530; upper, gray and black ROC curves)  versus the 1990 American 
College of Rheumatology clinical classification criteria (lower, yellow ROC curve) 
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Diagnosis of GCA 
2.1.2  The Use of a Nomogram to Visually Interpret Logistic Regression Prediction Model for 
Giant Cell Arteritis.  Neuroophthalmology 2018 
      Statistics literacy is essential for the interpretation of the medical literature and life-long 
learning (Ing, 2016).  Logistic regression with its odds ratios is one of the most used 
classification algorithms in medicine.  Odds are the ratio of the probability of an event 
occurring over the probability of the event not occurring.   In the context of our logistic 
regression prediction models, the odds ratios (O.R.) represent the constant effect of the 
predictor variable on the “likelihood” that the patient has GCA.  If the O.R. is unity, then the 
predictor variable does not affect the outcome of GCA.  If the O.R. is less than one, and the p-
value is statistically significant (confidence interval does not cross one) the predictor variable 
decreases the odds of having biopsy-proven GCA.  If the O.R. is greater than one, and the p-
value is statistically significant, the predictor variable increases the odds of having biopsy-
proven GCA.  Many clinicians may not realize that just examining the magnitude of the O.R. 
and its p-value when interpreting O.R. may not reveal which predictor contributes the most to 
the final risk score - it is also important to know if the predictor is a binary versus continuous 
variable.   
     From the logistic regression table shown in Figure 5, one might wrongly conclude that 
platelets with O.R. of 1.005 or age with an O.R. of 1.046 would not contribute much to the 
final risk score compared to jaw claudication (O.R. 3.656) and vision loss (O.R. 2.803).  
However, in the P-LR, jaw claudication and vision loss are binary variables, whereas platelets 
and age are continuous variables with a wide range.  The O.R. represents the increase in odds 
of GCA per unit increase in the predictor variable, and as such even small statistically 
significant O.R. of continuous variables can contribute much to the final risk score.  In the P-
LR model (n=530) the platelet level has an O.R. of 1.005082 which was rounded to 1.005 in 
Figure 5; as the confidence interval for platelets does not cross unity it is statistically 
significant.  The corresponding beta coefficient for platelets is ln (1.005082) = 0.0050691.  
Although a 1-unit change in the platelet value only results in a marginal increase in the odds, a 
10-unit increase in platelets has the effect of e^(βplatelets×10) = e^(0.0050691×10) = 1.05× increase in 
the odds. A 50-unit increase in platelets results in a e^(0.005691×50) = 1.29× increase in the odds.   
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     A nomogram is a graph of scaled variables that facilitates the approximate computation of 
a mathematical function via intersecting lines, and lucidly illustrates the relative importance of 
predictor variables in a multivariable logistic regression.     There were no previous 
applications of nomograms for GCA.  Although some feel nomograms are “outmoded medical 
relics”, (Grimes, 2008) the nomogram for the P-LR model clearly shows non-statisticians that 
the small O.R. of continuous variables may actually contribute more to risk than the seemingly 
larger O.R. of binary variables.  Although logit functions may be difficult for some clinicians 
to recall, the length and location of the lines associated with each predictor are a graphical 
representation of the variable’s corresponding O.R. and p-value (Zlotnik and Santos, 2013).    
 
Figure 5. The relationship between odds ratios (top) versus the Kattan nomogram risk score 
(bottom) for binary versus continuous variables on a logistic regression model (n=530) for 
GCA.            
       
Figure 5 Legend. 
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TA = temporal artery, Log = natural logarithm., CRP/ULN = C-reactive protein divided by its 
upper limit of normal, ESR = Westergren erythrocyte sedimentation rate.  Vision 
loss = ischemic optic neuropathy, central retinal artery occlusion, or other presumed ischemic 
vision loss. _cons = constant., ESR = erythrocyte sedimentation rate; 
CRP_divide_by_ULN = C-reactive protein divided by its upper limit of normal; 
TA_tender_noPulse = Clinical temporal artery abnormality (tenderness and/or decreased or 
absent pulse); New-Headache = new-onset headache 
 
Kattan-style nomograms are used for binary LR predictive models.  To use the Kattan 
nomogram, a vertical line is drawn from the value of the predictor variable down to the score 
scale.  For example, a platelet level of 433 contributes about 4.5 points.  The sum of the scores 
for all the predictor provides a total score, which can be converted to a risk probability for 
GCA. 
 
2.1.3 Support Vector Machines and Logistic Regression to predict temporal artery biopsy 
outcomes.  Can J Ophthalmol. 2019  
 
     Although the P-LR model (n=530) was serviceable, we sought to decrease its 18% 
misclassification rate, and explored an alternative classification algorithm.  Machine learning 
techniques such as support vector machines (SVM) are being increasingly recognized in 
medicine and ophthalmology (Lee et al., 2017).  In a 2014 abstract Lee et al. reported that a 
SVM algorithm had 100% classification accuracy in their test set of 40 patients, out of a total 
dataset of 182 TABx patients (Lee et al., 2014).  SVM is a supervised machine learning 
algorithm that identifies the hyperplane (decision boundary function) that best partitions and 
classifies a set of data. Support vectors are the data points at the edge of each class closest to 
the hyperplane that if removed, would alter the position of the hyperplane partition. The 
optimum hyperplane provides the widest margin between the hyperplane and the data points in 
the two separate classes.  SVM is often combined with kernelling, a method of pattern analysis 
that can map data into a higher dimensional space so that even non-linear hyperplanes can be 
determined.   
     We used the patient data from the P-LR set and applied it to a SVM model (Ing, Su, et al., 
2019).  The SVM model was optimally tuned with gamma= 0.01267 and cost = 26.466, with 
133 support vectors.  The AUROC/misclassification rate/false- negative rate for the P-LR 
versus SVM respectively were 0.827/0.184/0.524 and 0.825/0.168/0.571.  On DeLong’s test, 
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there was no statistically significant difference between the AUROC of the two models.  As 
the discrimination of the two models was almost identical, the extra complexity of the SVM 
algorithm was not warranted.  SVM does not provide direct probability estimates, which 
require calculation using cross-validation. SVM had a slightly larger-than-average precision 
and a slightly smaller misclassification rate but also had a higher false-negative rate compared 
with logistic regression. In the management of GCA, the greatest penalty is with false-
negative errors, as untreated GCA may result in irreversible blindness or rarely death. As such, 
SVM was not advantageous to logistic regression for the classification of GCA in our dataset 
of 530 TABx subjects with 10 covariates. 
 
2.1.4  Neural network and logistic regression diagnostic prediction models for GCA: 
development and validation.  Clinical Ophthalmology, 2019 
     As the SVM prediction model did not decrease the false-negative rate of TABx we turned 
to a neural network (NN) model.  NNs are akin to putting many layers of logistic regression 
functions together.  Compared to the lucid odds ratios of LR, that can suggest the relative 
contribution of predictor variables to risk, NNs are a “black box”.  (See Figure 6) However, 
unlike LR, NN can determine non-linear relationships without the specification of polynomial 
terms.  NNs are data-intensive and as such, my colleagues and I recruited a second wave of 
patients from different North American medical centres to increase our dataset.  The same 
predictor variables were used. 
 
Figure 6. Diagram of the neural network model.   
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Figure 6 Legend.  The neural network has 10 input predictor variables, 4 hidden nodes in a 
single hidden layer, and 1 output which codes for the diagnosis of GCA.  Each of the 10 inputs 
connects to a hidden node and is associated with a unique weight (the black numbers at the 
right of the rectangle).  The hyperbolic tangent activation function varies from -1 to +1.5  The 
sum from each of four weighted hidden node values (red numbers) contributes to the final 
output. 
 
     Only one other NN model has been described in the GCA literature (Astion et al., 1994).  It 
was developed from a database of 807 vasculitis patients, of whom 214 had the diagnosis of 
GCA.  Astion et al’s NN was intended for the classification of vasculitis, rather than the 
diagnosis of GCA in individual patients.  Their NN also required the result of the TABx; did 
not consider vision loss (one of the most feared complications of GCA), C-reactive protein or 
platelets; had no external validation; and assigned missing data a value of zero. 
     Of the 1,833 patients who underwent chart review for the NN-LR model, we had complete 
information on 1,201 (66%) of them.  Three hundred patients had biopsy-proven GCA 
(BPGCA) and complete information.  The patients with positive TABx had statistically 
significant greater age, temporal artery pulselessness or tenderness, jaw claudication, vision 
loss, and acute phase reactant bloodwork values than the negative biopsy group.  (Table 2)  
 
Table 2. Characteristics of subjects with positive versus negative temporal artery biopsy. 
     
 Jaw claudication is not a common symptom, but prevalent in our patients (see Table2).  
 
5 The hyperbolic tangent function (TanH) is a sigmoid function.  The advantage of the hyperbolic 
tangent function is that it is not limited to only positive outputs in the hidden layer.  TanH is the 
centred and scaled version of the logistic function and transforms values to be between -1 and +1. 
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Perhaps jaw claudication was overdiagnosed by some of the clinicians that contributed to the 
data, and see Chapter 6, page 85 for further comment. 
     Vision loss is one of the most feared sequelae of GCA and as such, this parameter is 
specifically reviewed in our large cohort of patients.  Of the 1,833 subjects who underwent 
TABx, there were 361 patients with ischemic vision loss.  In 171 (47.3%), further details of 
fundoscopy and the ophthalmic history were available; 59 had BPGCA and 112 did not.  Of 
the 59/300 (19.7%) patients with BPGCA and vision loss, 49 (83%) had anterior ischemic 
optic neuropathy (AION) that was bilateral in four (7%) subjects; three subjects (5%) had 
posterior ischemic optic neuropathy, six subjects (10%) had retinal arteriolar occlusion and 
one patient (2%) had a central retinal vein occlusion. The average age of the BPGCA patients 
with vision loss was 77.9 years and 59% were female.  
     Of the 112 patients with negative TABx and vision loss, 64 (57%) were deemed to have 
non-arteritic AION (NAION), and there were no cases of bilateral simultaneous AION. The 
average age of the negative biopsy group with vision loss was 74.1 years, and 61% were 
female.  Twenty-six patients (23%) in the biopsy-negative group had a retinal arterial 
occlusion, twenty-three central, one hemi-retinal, and two branch. 
     On multivariable logistic regression (n=1,201), platelets, jaw claudication, vision loss, log 
C-reactive protein, log erythrocyte sedimentation rate, headache, and clinical temporal artery 
abnormality were statistically significant predictors of a positive TABx (all p ≤0.05)   
 
Table 3. Multivariable logistic regression for the outcome of biopsy-proven GCA (n=1,201) 
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Figure 7. The Effect Summary plots the LogWorth values for the effects in the logistic 
regression model (n=1,201).   
 
Figure 7.  The logworth for each model effect, defined as -log10(p-value). This transformation 
adjusts p- values to provide an appropriate scale for graphing. A value that exceeds 2 is 
significant at the 0.01 level, because – log10(0.01) =2.   
 
 Revelations from the final LR model (n=1,201) include:  
i) Age, platelets, jaw claudication and vision loss were the most valuable predictors for GCA 
as shown on the Effect Summary plot (Figure 7).  The maintenance of age and acute phase 
reactant predictors as continuous variables helped to optimize our prediction models. Of the 
1,833 subjects who underwent TABx, 1,515 of them had accompanying platelet levels.  The 
mean/median platelet count X 109/L was 372/342 in the positive TABx group, and 283/264 in 
the negative TABx group (p<0.001) (Ing, Miller, et al., 2019). Maintaining bloodwork as 
continuous variables instead of dichotomizing (e.g. platelet level above or below 400 X 109/L) 
rendered platelets a stronger predictor for GCA than ESR or CRP.   
ii) Neither female gender nor diplopia were strong predictors of GCA.  Although more 
patients with GCA are women, female sex is not a strong predictor for GCA.  The female 
predominance of GCA is consistent with 2016 Canada census report that of citizens 65 years 
of age or older, the female: male ratio was 1.2.  For the 85 years and older population, there 
were two women for every man (Statistics Canada, 2017a).  “Every country with reliable 
health statistics reports that women live longer than men.” (Harvard Health Publishing and 
Harvard Medical School, 2010; Ortiz-Ospina and Beltekian, 2018)  Diplopia may be a poor 
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predictor of GCA because patients who lose vision in one or both eyes are usually less likely 
to experience binocular diplopia. 
     The area under the receiver operating characteristic curve/Hosmer-Lemeshow P for LR 
was 0.867 (95% CI, 0.794, 0.917)/0.119 vs NN 0.860 (95% CI, 0.786, 0.911)/0.805, with no 
statistically significant difference between the areas under the curves (P=0.316).  The NN 
model had 17% fewer false negatives than the LR model.   The misclassification rate/false-
negative rate of LR were 20.6%/47.5% versus 18.1%/30.5% for NN, respectively.  Missing 
data analysis did not change the results.  Misclassification remains a concern, but the cut-off 
values for 95% and 99% sensitivities were posted for use with the online calculator 
(https://goo.gl/THCnuU).   
     A probability score cut-off of 7% provides approximately 99% sensitivity to detect biopsy-
proven GCA.  In our study, electing to biopsy only those patients with a risk score of 7% or 
greater would have resulted in 0.8% false negatives, but the avoidance of 14% of the TABx 
that eventually were deemed negative.  In 2016 the estimated costs of a TABx in Australia and 
UK were £253 and £514 respectively (Cristaudo, Mizumoto and Hendahewa, 2016; Luqmani 
et al., 2016). 
     The LR-NN prediction models are the largest in the literature, and the only models 
compliant with the rigour of the transparent reporting guidelines for prediction rules 
(TRIPOD;  see Appendix H) (Collins et al., 2015).  The prediction models are unique in that 
they contained data from multiple centres in North America, with both ophthalmology and 
internal medicine patients, which enhances generalizability, and allowed for geographic 
external validation.  The free, user-friendly online calculator (https://goo.gl/THCnuU) allows 
clinicians a method to determine objectively the risk score of patients with suspected GCA 
prior to TABx. 
     Our NN-LR study did not appear to be compromised by the possible biases of i) biopsy 
length, ii) unilateral versus bilateral TABx, (Danesh-Meyer et al., 2000) or iii) referral from 
ophthalmology versus internal medicine sources. 
i)  In 1,501/1,833 (82%) of subjects, the biopsy length was readily available. The average length 
was 2.25 cm (±0.95) in the 1,142 subjects with a negative TABx, and 2.32 cm (±0.90) in the 
359 with a positive TABx, with no statistically significant difference (p=0.24). 
ii) Although some clinicians routinely perform bilateral TABx in hopes of decreasing the risk 
of false-negative biopsy, “routine bilateral biopsies are discouraged” (Weyand and Goronzy, 
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2014).  Of the 1,105/1,833 subjects that had information on unilateral versus bilateral biopsy, 
437 (40%) had bilateral TABx. The proportion of BPGCA in the unilateral TABx group was 
162/667 (24.3%), and that in the bilateral TABx group was 109/437 (24.9%), which was not a 
statistically significant difference (p=0.80).  
iii) The prediction profile curves for the model re-emphasize the ability of actuarial algorithms 
to calculate multiple risk factors, especially for continuous non-linear predictors such as age and 
bloodwork.  (See  
 
Figure 8) 
 
 
 
Figure 8. Prediction risk profile curves of the logistic regression model with linear and non-
linear responses. 
 
Figure 8.  The risk profile curves from the logistic regression model (n=1,201) shows the 
output for the hypothetical case of an 80-year-old man with jaw claudication, but no new-
onset headache, no temporal artery tenderness, and no diplopia.  The erythrocyte 
sedimentation rate (ESR)is 49 mm/hour with C-reactive protein level (CRP) that is twice 
normal, and a “normal” platelet of 350 x 109/L.  In the top readout, the patient retains 
normal vision and the estimated risk for biopsy-proven GCA (BPGCA) is 31%.  In the bottom 
readout, the patient has vision loss, and the risk of BPGCA increases to 54%.   Note the age 
and bloodwork variables are continuous variables and do not have a linear response (see 
arrows).  Few humans can mentally calculate the risk score from ten predictor variables, 
especially those with a non-linear response. 
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Figure 9. Boxplots of the predicted risk scores of the Neural Network and Logistic 
Regression Models for the positive and negative temporal artery biopsy groups. 
     
Figure 9 Legend.  LR_model= logistic regression; NN_model = neural network model 
The horizontal line contained within the rectangle of the boxplot is the median value.  The lower 
hinge of the box is the 25th percentile, and the upper hinge the 75th percentile.  The dots above 
the top of the box plot are outliers with high-risk scores in the negative biopsy group. 
 
     Unfortunately, prediction models can still fail as infrequently GCA can present in an occult 
fashion, or more commonly because other diseases can mimic the symptoms, signs and, 
serology of GCA, as illustrated by the case reports (Section 2.3).  The high score outliers in 
the negative TABx group of Figure 9 represent either false negative TABx or the overlap of 
symptoms and signs of GCA with other diseases  (see Section 2.3 Differential Diagnosis).  
These outliers are problematic when trying to improve classification algorithms. 
     Patients with a positive TABx but ESR, CRP and platelets within normal limits 
(seronegative GCA) are also enigmatic for classification algorithms.  Normal serology (the 
combination of ESR < 50 mm/hour and, CRP and platelets at or below their upper limit of 
normal) was present in 30 of the 300 subjects with complete information and biopsy-proven 
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GCA. Six of these “seronegative” GCA patients (6/30=20%) were diagnosed as healed 
arteritis (See page 55).  In 2013 Grzybowski and Justynska summarized 11 publications with 
GCA and normal serology (Grzybowski and Justynska, 2013).    In the Solans-Laque et al 
series of 418 patients with biopsy-proven GCA, 3.3% of patients had negative ESR and CRP 
at the time of diagnosis (Solans-Laque et al., 2018).  Perhaps patients with seronegative GCA 
have early stage disease; medications such as non-steroidal anti-inflammatory drugs and 
statins may reduce ESR or possibly CRP. 
     In the P-LR and NN-LR study patients with healed arteritis were considered to have a 
positive TABx if they had a steroid response and were maintained on steroids after the result 
of TABx returned.  In the NN-LR study, 1.7% of all subjects carried the diagnosis of healed 
arteritis and accounted for 20% of the seronegative GCA patients.  If we excluded subjects 
with healed arteritis from our study, our model would have performed even better; the LR 
AUROC improves from 0.815 (n=1,201) to 0.832 (n=1,160).   However, since healed arteritis 
is a scenario that can confront clinicians, we maintained these patients in the dataset. 
 
2.2 Temporal Artery Biopsy 
 
2.2.1 Systematic Review of the Yield of TABx for Suspected GCA.  Neuroophthalmology, 
2018 
     Temporal artery biopsy (TABx) remains pivotal in the diagnosis of GCA (Danesh-Meyer, 
2012) and the reference standard confirmatory test for GCA.  As such, the expected positive 
yield (utility rate) of TABx is important to ascertain.  The utility rate of a TABx indicates how 
many biopsies are positive for GCA out of the total number of TABx performed, and is a 
different metric than the diagnostic sensitivity of TABx.  The utility rate provides a possible 
benchmark for decisions regarding the under/overutilization of TABx, may assist in decision-
making for GCA, and can aid in the evaluation of non-invasive alternatives such as ultrasound  
and high resolution MRI for the investigation of GCA.   There was no systematic review of the 
literature on this topic prior to our work which was unique to the International Prospective 
Register of Systematic Reviews (PROSPERO) ID=CRD42017078508.  This prototypal 
review of the last two decades of the TABx literature encompassed 4,344 GCA studies, of 
which 113 had relevant, unbiased TABx results for meta-analysis (Ing, Wang, et al., 2018).  
Of the 30,898 TABx, 7379 (23.9%) were positive for GCA. The yield of TABx from the 
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articles had a right skew distribution with a median yield of 0.25 (95% confidence interval 
0.21 to 0.27) and an interquartile range of 0.17 to 0.34.  The I2 statistic of 92% meant that 
heterogeneity was too large to perform a meta-analysis, but a univariate meta-regression 
suggested that age was the only statistically significant patient factor associated with TABx 
yield.  The 25% median utility rate of TABx reinforces the conviction that prediction rules for 
GCA (using pre-biopsy criteria) might increase the yield of TABx by avoiding biopsy of 
subjects at very low-risk for GCA.        
     The relevance of the systematic review of TABx in modern medical practice is not 
anachronistic with the emergence of ultrasound.  Although the European League Against 
Rheumatism (EULAR) guidelines propose that at centres with appropriate equipment and 
sufficient radiologic expertise modalities such as doppler ultrasound or perhaps MRI may be 
first-line investigations for suspected GCA (Dejaco et al., 2018), others do not concur 
(Danesh-Meyer, 2012; Bilyk et al., 2018; González et al., 2018).  Due to the myriad of 
potential side effects with long term glucocorticoid treatment (see Section 1.2 page 14), the 
British Society of Rheumatology (BSR) Guidelines for GCA (Mackie et al., 2020) strongly 
recommends that “Patients with suspected GCA should have a confirmatory diagnostic test. 
This could be either a temporal artery biopsy at least 1cm in length, or an ultrasound of the 
temporal and axillary arteries, or both.”  Figure 1 of the BSR guideline is a flow diagram (see 
Figure 19) with 3 risk categories and 5 possible initial ultrasound investigation pathways, but 
3/5 of the ultrasound scenarios eventuate in TABx.   
     Three- dimensional fat-saturated contrast enhanced vessel-wall MRI at 3 Tesla has recently 
been suggested to increase diagnostic accuracy for GCA (Poillon et al., 2019). Perineural 
enhancement of the optic nerve on MRI has been described with GCA but is non-specific 
(Serrano Alcalá et al., 2019). As of 2020, there are no dedicated fast-track ultrasound facilities 
for GCA assessment in the Greater Toronto Area which is Canada’s most populous 
metropolitan area.  At most medical centres in Toronto, ultrasound of the temporal arteries and 
cranial MRI for GCA are impractical for GCA work-up because these outpatient studies may 
require more than three weeks to obtain.6 
     Furthermore, 2019 practice preference survey showed that the vast majority of North 
American and European neuro-ophthalmologists and Canadian rheumatologists still prefer 
 
6 CT of the orbit and sinuses are routinely obtained in GCA suspects within 12-24 hours, concurrent with 
glucocorticoid initiation, to exclude sinusitis. 
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TABx over ultrasound (Ing, Xu, et al., 2019).  A systematic literature review and meta-
analysis estimated the sensitivity of TABx at 77% and concluded that TABx is not less 
sensitive than temporal artery imaging (Rubenstein et al., 2019).  A second systematic review 
of the literature comparing imaging and pathology confirmed that the hypoechoic halo sign on 
temporal artery doppler ultrasound had 68% (95% CI: 57–78) sensitivity and 81% (95%CI: 
75–86) specificity compared with a positive TABx (Rinagel et al., 2019).    Conditions such as 
arteriosclerosis, other forms of vasculitis (ANCA-associated vasculitis) and infections can 
cause a false-positive halo sign on Doppler ultrasound (De Miguel et al., 2018; Bardi and 
Diamantopoulos, 2019). Even the EULAR task force conceded that TABx “should be 
performed in all cases, where GCA cannot be confirmed or excluded based on clinical, 
laboratory and imaging results.” (Moiseev et al., 2019)  
     Skip lesions (see Section 2.2.3, page 37) aside, adequate length negative TABx have 
clinical value if they allow glucocorticoids to be stopped (Hedges, III, Gieger and Albert, 
1983).  TABx also may reveal alternative diagnoses such as syphilis (Smith, Israel and Harner, 
1967), sarcoidosis, (Levy and Margo, 1994), renal cell metastases, (Ing et al., 1996) 
amyloidosis, (Ing et al., 1997) granulomatosis with polyangiitis (Ong Tone, Godra and Ing, 
2013) and other antineutrophil cytoplasmic antibody-associated vasculitides, calciphylaxis, 
Mönckeberg’s medial calcific sclerosis and zoster sine herpete which may not be discovered 
in an expedient fashion without tissue pathology (Ing, Wang, et al., 2018). 
          TABx are pivotal to the diagnosis of GCA (Danesh-Meyer, 2012) and performed almost 
exclusively under local anaesthesia as an outpatient procedure.  Many patients requiring TABx 
are on anticoagulation for other age-related ailments, and biopsy of a blood vessel is prone to 
haemorrhage.   As such the supporting articles on perioperative anticoagulant considerations 
and local anaesthetic technique for TABx are germane. 
 
 
2.2.2 New oral anticoagulants and oculoplastic surgery.  Canadian Journal of Ophthalmology, 
2014                             
 
     During most operations, surgeons strive to avoid blood vessels.  TABx requires intentional 
sampling of an artery with an increased risk of haemorrhage.  The potential for bleeding is 
compounded when an elderly patient referred for TABx is also on anticoagulants for co-
morbid conditions such as atrial fibrillation, stroke or myocardial infarction.  Hemostasis is 
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essential in these elderly outpatients who are quickly discharged from the clinic post- 
procedure.   When the new direct oral anticoagulants (non-Vitamin K oral anticoagulants) 
dabigatran, apixaban, and rivaroxaban emerged circa 2010, oculoplastic surgeons knew little 
about them, and there were no reversal agents available at that time.  The Canadian Society of 
Oculoplastic & Reconstructive Surgery asked me to review this topic.  My co-author was a 
haemotologist and we scrutinized:  i) the pharmacology of the newer anticoagulants, including 
their duration of action and mechanism of excretion,  ii) the herbal and homoeopathic 
supplements that could cause bleeding and  iii) the risks and potential gains of stopping versus 
continuing anticoagulants prior to periorbital soft tissue procedures such as TABx (Ing and 
Douketis, 2014).    
     In patients with suspected GCA who cannot stop their anticoagulation whether it be a direct 
oral anticoagulant or warfarin, and in whom ultrasound and MRI are deemed inadequate for 
diagnosis, my recommendation for soft tissue procedures such as TABx are:  1)  discontinue 
over-the-counter medications such as vitamin E (see Appendix A for expansive list), optimize 
treatment of hypertension, and if possible dispense a lower-dose formulation of the 
anticoagulant perioperatively.  During TABx in the reverse Trendelenburg position, if initial 
local anaesthetic administration does not result in a large hematoma I continue with the 
procedure.  Occasionally suction and oxidized regenerated cellulose may be helpful.  Two 
permanent ligatures are placed at the proximal end of the vessel and one is secured distally.  
After the biopsy, a compressive head dressing is placed over the wound for three days to 
decrease the risk of haemorrhage.  I avoid any TABx if the internist suggests the bleeding risk 
is so high that the need for prothrombin complex concentrate, idarucizamab, adexanet alfa or 
aripazine should be considered (Ing, 2019c). 
 
 
2.2.3 Local anaesthesia and anxiolytic techniques for surgery.  Clinical Ophthalmology, 2019  
 
     The adroit administration of local anaesthetic and anxiolytics is paramount to the success of 
awake surgeries such as TABx “as it ensures patient cooperation, aids hemostasis, and 
enhances the patient’s surgical experience and perception of good care.” (Ing, Philteos, et al., 
2019)  Lidocaine cream prior to needle injection may decrease patient discomfort.  It is critical 
to map accurately the location of the artery with a marker prior to anaesthetic injection.  If 
ultrasound has been performed, and TABx confirmation still is requested, the vessel segment 
GCA  2.2 Diagnosis and Temporal Artery Biopsy 
 
39 
 
corresponding to the hypoechoic halo on the symptomatic side should be preferentially 
biopsied.    In patients with a readily visible or palpable artery, epinephrine can be 
incorporated with the initial local anaesthetic injection. The epinephrine in local anaesthetic 
causes vasospasm and diminution in arterial diameter, making it more difficult to identify the 
artery.  Therefore, in patients with indeterminate surface vessel markings and poor arterial 
pulsation, I refrain from using epinephrine in the local anaesthetic solution until after the 
vessel is identified subcutaneously. Local anaesthetic is injected approximately 1 centimetre 
(cm) away from either side of the vessel but not into the vessel. If there is any concern that the 
vessel markings will be obscured by the prep solution, the vessel location can be scratched 
with a needle tip prior to the antiseptic scrub.  Our local anaesthetic paper is one of the few 
papers that summarizes the ancillary anxiolytic techniques that can be used during awake 
procedures such as TABx including sedatives, stress balls and hand massage, breathing 
exercises, verbal anaesthesia, music relaxation, vibration, and visualization techniques. 
    It is plausible that the aforementioned anticoagulation and local anaesthetic considerations 
were neglected in the recent Role of Ultrasound Compared to Biopsy of Temporal Arteries in 
the Diagnosis and Treatment of Giant Cell Arteritis (TABUL) study.  In 7.3% of the TABUL 
study subjects, instead of a temporal artery specimen, structures such as a vein, fat, muscle or 
a nerve were harvested.  This is an unacceptably high failure rate.  Of the temporal artery 
specimens obtained in the TABUL study, a remarkable 43% were less than 1 cm in length  
(Luqmani et al., 2016).  To avoid skip lesions the BSR guidelines advocate a biopsy of at least 
1 cm (Mackie et al., 2020).  Oh et al.’s pathology study found that a 1.5 cm biopsy was the 
optimum length threshold to avoid a false-negative GCA diagnosis on pathology, and that 
each millimetre increase in TABx length increased the odds of a positive biopsy by 3.4% 
(p=0.024) (Oh, Wong, Gill, et al., 2018). 
 
2.2.4 Practice Preference Survey: Temporal Artery Biopsy versus Doppler Ultrasound in the 
Work-up of Giant Cell Arteritis.  Journal of Neuro-ophthalmology, October 2019  
     To review, TABx has long been acknowledged as the “gold standard” confirmatory test in 
patients with suspected GCA.  Of the imaging techniques described for GCA including MRI, 
MR angiography, computed tomographic angiography and positron emission tomography, in 
2018 EULAR recommended Doppler ultrasound  (US) of the temporal +/- axillary arteries as 
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the first imaging modality in patients with suspected predominantly cranial GCA at centres 
with appropriate equipment and sufficient radiologic expertise (Dejaco et al., 2018).  The 2020 
British Society of Rheumatology guidelines for GCA (Mackie et al., 2020) suggested the use 
of a confirmatory test for GCA which can either be, “ a temporal artery biopsy at least 1cm in 
length, or an ultrasound of the temporal and axillary arteries, or both.”   
     Given the above recommendations, my objective was to determine if ophthalmologists and 
neurologists currently prefer ultrasound or TABx as their test of choice to confirm GCA.  
There is debate between the merits of these two investigations (Bilyk et al., 2018; González et 
al., 2018) and a systematic review has questioned the reliability of US in comparison to TABx 
(Rinagel et al., 2019). 
     No prior audits have been published regarding practice preferences in the work-up of GCA.  
Our 2019 online survey canvassed ophthalmologists and neurologists in North America, Europe 
and, Israel; Canadian rheumatologists were also included.  We also solicited EULAR but did 
not receive any results from European rheumatologists. 
     In total 406 surveys were completed in a median time of 22 seconds. The estimated survey 
response rate was 18% (see Appendix D).  There were 253 (62.3%) ophthalmology and 
neurology respondents (O&N) from North America, 82 (20.2%) O&N participants from Europe, 
and 71 (17.5%) Canadian rheumatologists.    
     The survey margins of error (x) were determined using the calculator from  
https://www.surveysystem.com/sscalc.htm and reported as a 95% confidence intervals in the 
format (+/- x)95%CI (see Appendix D). 
     The overall results from the O&N group showed that 303 (90.5 +/-2.9%)95%CI preferred 
TABx as their confirmatory test for GCA, whereas 22 (6.6 +/-2.4%)95%CI favoured Doppler 
ultrasound.  Of the O&N practitioners who preferred TABx, 268 (88.4 +/-3.3%) 95%CI indicated 
they use TABx exclusively, and 35 (11.6 +/- 3.3%)95%CI ordered both TABx and US but 
preferred TABx. Ten of the 335 O&N participants (3.0 +/-1.8%)95%CI did not order TABx or 
ultrasound for their GCA suspects; one used MRI head exclusively, one endorsed ultrasound of 
the central retinal artery, three deferred work-up decisions to their group’s neuro-
ophthalmologist, and the remaining five respondents did not provide a reason. 
     On a regional basis, 242/253 (95.7 +/- 2.31%)95%CI of North American O&N preferred TABx 
as their confirmatory test, compared with 61/82 (74.4 +/- 7.7%)95%CI of their European 
counterparts. Doppler ultrasound was the favoured test in 2/253 (0.8 +/- ~1.13%)95%CI of North 
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American O&N versus 20/82 (24.4 +/-7.6%)95%CI of European physicians. The regional 
differences were statistically significant as the confidence intervals do not overlap; also, the 
non-survey-weighted two-sample test of proportions, as well as Pearson chi2 test, showed p < 
0.001 (see Appendix D). 
     Seventy-one Canadian rheumatologists were surveyed, and 64/71 (90.1 +/- 6.0%)95%CI 
preferred TABx, 4/71 (5.6+/- 4.6%) 95%CI endorsed Doppler ultrasound, and 3/71 (4.2+/- 3.9%) 
95%CI ordered neither. One rheumatologist from the latter group used MRI head as the preferred 
investigation. 
     With regards to test preference and clinician speciality, 34/37 (91.9%) neurologists, 269/298 
(90.3%) ophthalmologists and 64/71 (90.1%) rheumatologists endorsed TABx as their 
confirmatory test for GCA, with no statistically significant difference on repeated two-sample 
test of proportions (all p-values >= 0.75, Appendix D). 
     In summary, as of July 2019, most O&N clinicians in North America and Europe prefer 
TABx to ultrasound in the work-up of GCA. The greater proportionate use of US in Europe 
versus North America may be because of the EULAR guidelines. The advantages of US over 
TABx include its non-invasive nature and lower cost. US can assess both the temporal and 
axillary arteries and increase the diagnostic yield (Luqmani et al., 2016), and serial US can help 
monitor the effect of treatment. Also, if pathology confirmation is desired, ultrasound may help 
guide the optimal site for TABx. However, US is highly examiner-dependent technique 
(Landau, Savino and Gruber, 2013).  Systematic review of articles comparing imaging and 
pathology showed that the hypoechoic halo sign on temporal artery Doppler ultrasound had 68% 
(57%,78%)95%CI sensitivity and 81% (75%,86%)95%CI specificity compared with a positive 
TABx (Rinagel et al., 2019). Conditions such as atherosclerosis can cause false-positive halo 
signs on Doppler ultrasound (De Miguel et al., 2018). The low 39% sensitivity for TABx 
compared with ultrasound in the TABUL study is attributable to deficiencies in the performance 
of TABx (see Section 2.2.3, page 37).   Furthermore, the TABUL study used the ACR clinical 
classification criteria to diagnose GCA, but these were not intended for same. Even the EULAR 
task force conceded that TABx “should be performed in all cases, where GCA cannot be 
confirmed or excluded based on clinical, laboratory and imaging results.” (Moiseev et al., 2019) 
     A potential weakness of our survey is the 18% survey response rate, but this may be an 
underestimate because some members had multiple listings on the same society membership; 
retired members were still listed on the internet line; members who belonged to both neuro-
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ophthalmology and the oculoplastic societies were double-counted; and pediatric subspecialists 
would be unlikely to encounter patients with GCA. Our report of 95% confidence intervals 
mitigates bias in the response rates. Furthermore, the direct correlation between response rate 
and study validity has been questioned (Morton et al., 2012).  Some surveys with low response 
rates, even as low as 20%, may yield more accurate results than studies with response rates of 
60% to 70% (Visser et al., 1996).  Investigations with low response rates may be only marginally 
less accurate than those with higher response rates (Holbrook, Krosnick and Pfent, 2007). 
     The results of this physician survey elucidated geographic and physician speciality trends in 
the work-up of GCA, and may aid in the assessment of future preferred practice patterns.
2.3 Differential Diagnosis 
 
     Case reports can be “valuable resources of unusual information that may lead to new 
research and advances in clinical practice.  Many journals and medical databases recognize the 
time-honoured importance of case reports as a valuable source of new ideas and information in 
clinical medicine.” (Ortega-Loubon, Culquichicón and Correa, 2017)  TABx can occasionally 
reveal unsuspected diagnoses as illustrated by the following case reports and the other entities 
(see Section 2.2.1, p 35).  The presentation of GCA can especially mimic malignancy or 
infection or vice versa.  We reported two patients whose clinical presentations were confused 
with isolated GCA. 
2.3.1 Systemic amyloidosis with temporal artery involvement mimicking temporal arteritis.  
Ophthalmic Surgery and Lasers, 1997 
     The first patient was a 77-year-old man with jaw claudication, arthralgias, myalgias, weight 
loss and ESR 35 mm/hr, but no vision loss.  He was eventually diagnosed with light chain 
amyloidosis and multiple myeloma after amyloid was noted on the TABx (Ing et al., 1997). 
As of 2017, there were 14 other case reports of light-chain amyloidosis mimicking GCA 
(Ghinai et al., 2017).  Both GCA and amyloidosis can cause the symptoms of polymyalgia 
rheumatica or jaw claudication.  Also, amyloidosis is purported to cause non-arteritic ischemic 
optic neuropathy (Neri et al., 2013).  Ghinai et al. advocates Congo red staining of TABx 
specimens and suggests that amyloidosis should be considered in GCA suspects with an 
atypical response to glucocorticoids. 
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2.3.2 Polyangiitis overlap syndrome with Granulomatosis with polyangiitis (Wegener's) and 
giant cell arteritis. Can J Ophthalmology, 2013 
     The second case report was of a 61-year-old woman who presented with headache, 
diplopia, possible jaw claudication, elevated ESR 65 mm/hr and thrombocytosis of 435 x 103 
mm3 with transmural inflammation on TABx (Ong Tone, Godra and Ing, 2013).  In addition, 
she had abnormally high anti-neutrophil cytoplasmic antibodies directed to proteinase 3 and 
fibrocellular glomerular crescents on kidney biopsy.  The importance of identifying this GCA 
- granulomatosis with polyangiitis (Wegener’s) overlap syndrome is that in addition to 
systemic glucocorticoids, treatment with cyclophosphamide or rituximab is required.   
Antineutrophil cytoplasmic antibody-associated vasculitis and GCA are the most common 
primary systemic vasculitides in adults. As of 2018, 14 other cases of GCA and 
granulomatosis with polyangiitis have been reported (Hassane et al., 2018).
 
 2.4 Epidemiology of GCA 
 
     GCA is a burgeoning public health concern and the second theme of this thesis is the 
epidemiology of GCA.  As our population ages, the incidence of GCA will likely increase.  By 
2050 in the United States alone, the estimated cost of GCA due to visual impairment and 
glucocorticoid-related fractures is estimated to be US$76.3 billion and US$6.6 billion 
respectively (De Smit, Palmer and Hewitt, 2015).  The incidence and predispositions for GCA 
are important to determine for public health planning.  Thus, the motivation for the incidence 
study for GCA which has not been well documented in Canada, and the geoepidemiologic 
analysis of the incidence of herpes zoster versus the incidence of GCA in different countries.  
No prior incidence study had been performed in Canada’s most populous province, Ontario.  
Also, no prior ecologic analysis has compared the incidence rates of zoster and GCA. 
 
2.4.1 The incidence of GCA in Ontario, Canada.  Canadian Journal of Ophthalmology, 2019 
     Disease incidence is important to document for epidemiologic reasons and to facilitate the 
allocation of public health expenditures.    The annual incidence of GCA (IRGCA) ranges from 
1.6 to 34.3 cases per 100,000 individuals 50 years of age or older and varies according to 
geographic location.  In general, Scandinavia is thought to have the highest incidence, and 
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Europe has an intermediate incidence.  Japan and Asia report few cases of GCA (Lee et al., 
2008; Gonzalez-Gay et al., 2010; Weyand, Liao and Goronzy, 2012; Moraña et al., 2019).   
     Prior to our incidence study (Ing, Lahaie Luna, et al., 2019), the only Canadian report was 
from Saskatchewan, a province which has only 3% of Canada’s population.  The 2007 
Saskatchewan study did not specify its enumeration method but found the incidence of biopsy-
proven GCA (BPGCA) to be 9.4 per 100,000 people over the age of 50 years (Ramstead and 
Patel, 2007).     
     Ontario is Canada’s most populous province with 38% of the nation’s population.  Despite 
a universal health care system, Ontario has no central registry of positive pathology results, 
and the provincial billing data does not distinguish GCA from other vasculitides.  As such we 
used two methods to determine the incidence of BPGCA in Ontario, Canada:  i) a 
retrospective pathology audit in Kingston, Ontario, a city with a single dominant medical 
provider, and a well-contained catchment area, and ii) an incidence estimate from provincial 
billing data of TABx in conjunction with a meta-analyzed expected positive yield for TABx in 
Ontario. 
     There were 35 subjects with positive TABx in the Kingston area over the 4-year period, 
from a population of 179,503 individuals 50 years of age or older (≥50 years) yielding a 
minimum cumulative annual incidence of BPGCA of 4.9 per 100,000 individuals over the age 
of 50 years.   
     Provincial billing data showed that there were 2,404 individual patients from Ontario who 
underwent 3,022 TABx (billing code Z815A) from July 1, 2015, to June 30, 2017; 
approximately 20% of GCA suspects in Ontario had bilateral TABx.  From the 2016 Canada 
census, the population of Ontarians 50 years of age or over was 5,143,610 persons (Statistics 
Canada, 2017b).  A literature search revealed five series of TABx with information on positive 
yield from Ontario, Canada.  Random effects meta-analysis of these five series found the 
positive yield of TABx in Ontario to be 0.21 (95% CI0.18–0.24) with I2 13.1% (Fig. 2). As 
such the incidence estimate of BPGCA from provincial billing data is 4.9 (95%CI 4.2–5.6) per 
100,000 persons 50 years of age or over which is in complete agreement with the Kingston, 
Ontario chart review.  Perhaps the lower IRGCA in Ontario compared with Saskatchewan is 
because of the greater ethnic diversity in Ontario.  The IRGCA in Ontario, Canada is also 
comparable to the rates reported in northern Germany, Australia, and Italy which are between 
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3.2 and 5.8 per 100,000 population 50 years of age or more (see Appendix B). The IRGCA are 
higher in Finland, Norway, the United Kingdom, the United States, Israel and, France in part 
because these figures included clinically diagnosed GCA as well as BPGCA (see Appendix 
B).  
 
Figure 10. Incidence rate calculations from provincial billing data and pathology lab audit. 
Figure 10.  The incidence of GCA in Ontario was estimated from temporal artery biopsy 
provincial billing data, and the meta-analyzed expected positive yield of TABx in Ontario.  
Also, the incidence of GCA in Kingston, ON, Canada was enumerated from hospital pathology 
audit in Kingston, ON noting the postal codes of patients with a positive biopsy.   In both 
methods, the corresponding population denominators were determined from Canada census 
data for patients 50 years of age and older.  Both techniques yielded a GCA incidence of 4.9 
per 100,000 patients 50 years of age or older.     
 
2.4.2 Does herpes zoster predispose to GCA: a geoepidemiologic study.  Clinical 
Ophthalmology, 2018 
     A possible immune trigger for GCA is infection.  In particular, there has been much 
controversy as to whether or not herpes zoster contributes to GCA, heightened by the recent 
availability of the zoster vaccines.  Infections theoretically can predispose to systemic 
vasculitis through mechanisms such as molecular mimicry, epitope spreading, immune 
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response to subdominant epitopes normally hidden from T-cell recognition, or bystander 
activation (Moiseev et al., 2017).   Gilden and Nagel found varicella zoster virus (VZV) in the 
temporal arteries of 73% of patients with BPGCA and proposed VZV as a possible trigger in 
the immunopathogenesis of GCA (Gilden et al., 2015; Nagel et al., 2015). Although the role 
of VZV in the development of GCA has not been substantiated by most other investigators 
and remains controversial, Gilden suggested adjunctive antivirals be considered in the 
treatment of GCA (Gilden and Nagel, 2016). 
     As previously mentioned, the incidence rate (IR) of GCA varies widely by country, being 
the highest in Scandinavian countries and lowest in Asia (De Smit, Palmer and Hewitt, 2015; 
Mahr et al., 2017).   
     I hypothesized that if VZV was a strong immune precursor for GCA, the IR for GCA 
(IRGCA) per country should mirror the local IR for herpes zoster IR (IRHZ).  No other 
publications have tested this original hypothesis.  With respect to ecologic studies in 
epidemiology, the unit of observation is the population. Our geoepidemiologic analysis is the 
first published ecologic study comparing incidence rates of herpes zoster and GCA.  
     To test this hypothesis, a literature search was performed and linear regression analysis 
using the published IRGCA and IRHZ from different countries was plotted.  Only 
countries/regions that had IRs available for both GCA and HZ were used for analysis.  Only 
incidence figures prior to the availability of the zoster vaccines were considered. Paired t-test 
was used to examine the time difference in year of publication between the GCA and HZ 
studies for each country.  
The IRs for both GCA and HZ were available for 14 countries and are plotted in Figure 11. 
IRGCA with: IRHZ in 50-year-olds was -0.51 (p=0.07), and IRHZ in 70-year-olds was -0.40 
(p=0.16). Linear regression with robust standard errors showed a regression coefficient (β) -
2.92 (95% CI -5.41, -0.43; p=0.025) between the IRGCA 50-year-olds, and the IRHZ in 50-year-
olds. For the IRHZ in 70-year-olds, no statistically significant linear dependence of the mean 
IRGCA on IRHZ was detected (β=-1.78, 95% CI -4.10, 0.53; p=0.12). White’s test did not 
suggest heteroscedasticity.  A two-sided p<0.05 was considered statistically significant. 
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Figure 11. Incidence of giant cell arteritis versus the incidence of herpes zoster per country.   
 
 
Figure 11.  The red line with a negative slope is the line of best linear fit using the least-
squares method.  The GCA incidence figure for Canada (from Saskatchewan) was the only 
one available at the time of the original study.   
 
     Our ecologic study does not support a positive biologic gradient between the IRHZ and 
IRGCA. Subgroup regression analyses of the per-country IRGCA and IRHZ, with and without 
overlapping timeframes were not statistically significant and did not show a positive 
regression coefficient (see Appendix E). 
     Our ecologic analysis of the incidence rates of herpes zoster versus GCA is unique in the 
literature (Ing, Ing, et al., 2018). Although there is potential for aggregation bias with any 
ecologic analysis, the results of this investigation support the conclusion that if there is an 
association between herpes zoster and GCA, it is not a strong one.  A retrospective cohort 
study found a modest statistical association between VZV and GCA, but given the infrequency 
of HZ in GCA concluded there are additional immunologic triggers for GCA other than HZ.  
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Furthermore, antivirals and the zoster vaccines did not consistently mitigate the risk of 
incident GCA (England et al., 2017). 
      Our published ecologic analysis was performed when the Saskatchewan study was the 
only Canadian IRGCA study available.     Repeating the analysis using the Ontario, Canada 
incidence data did not change the result. 
Figure 12. Incidence of giant cell arteritis versus the incidence of herpes zoster per country, 
using Ontario, Canada data. 
 
 
The red line with a negative slope is the line of best linear fit using the least-squares method.  
Substituting the incidence of GCA for Ontario, Canada did not change the results. 
 
     There is a possible effect of vitamin D on toll-like receptors and GCA, which might render 
latitude and sunlight in different countries as a confounder.  Vitamin D can affect the 
induction of cell differentiation and immunomodulation.    The production of Vitamin D is 
related to sunlight exposure and therefore latitude.  As mentioned earlier the activation of 
adventitial dendritic cells through TLRs may be the inciting factor in the immunopathology of 
GCA.  Vitamin D supplementation may down-regulate the expression of the TLRs and their 
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pro-inflammatory effect (Dickie et al., 2010; Adamczak, 2017).  Vitamin D has also been 
shown to boost immunity against herpes zoster (Chao et al., 2014).  A possible hypothesis is 
that vitamin D levels can confound the incidence rates of GCA and zoster such that:  i)  
Subjects using vitamin D supplementation may be less prone to developing zoster or GCA, 
regardless of their country of origin, latitude or sunlight exposure, and ii) areas with vitamin D 
deficiency would be expected to have higher rates of both zoster and GCA.  These conjectures 
are difficult to substantiate.   Global vitamin D levels are not accurately known, although there 
appears to be severe hypovitaminosis D in the Middle East and South Asia (Edwards et al., 
2012).  However, both these regions have a low incidence of GCA. 
 
     The contribution to original knowledge from the thesis publications in the context of the 
existing literature is summarized in Table 4 below.
 
2.5 Summary of Contributions to Original Knowledge in the Context of Existing 
Literature 
Table 4. Summary of Contributions to Original Knowledge in the Context of Existing 
Literature 
 
ABBREVIATED ARTICLE 
TITLE (with clickable link)  
 
CONTRIBUTION TO ORIGINAL KNOWLEDGE AND 
THE GIANT CELL ARTERITIS LITERATURE      
               
 
DIAGNOSIS OF GCA:  STATISTICAL PREDICTION MODELS 
Multivariable prediction model for 
suspected GCA.   2017  
This logistic regression (LR) model with 10 predictors (age, 
gender, new-onset headache, temporal artery tenderness or 
pulselessness, jaw claudication, vision loss, diplopia, platelet 
level, erythrocyte sedimentation rate and C-reactive protein) 
estimates the risk for GCA prior to TABx.  Age and 
bloodwork were maintained as continuous variables.  The LR 
rule was developed from multi-centre data and was one of the 
largest series of patients undergoing TABx for suspected GCA 
to date (n=530 complete cases).  It was one of the few/ only 
prediction models with   i) enough cases to support 10 
predictors, ii) geographic external validation, iii) compliance 
with the TRIPOD guidelines for model reporting (including 
missing data analysis), iv) inclusion of both internal medicine 
and ophthalmology patients, and v) a user-friendly online risk 
calculator.    Age, jaw claudication, vision loss, platelets, and 
the log-transformed CRP were statistically significant 
predictors for GCA.   
GCA Summary of Knowledge Contributions 
 
50 
 
This primary LR model handily outperformed the 1990 
American College of Rheumatology Classification Criteria for 
GCA, which many have inappropriately used in the past to 
diagnose GCA.   
Nomogram to Visually Interpret a LR 
Prediction Model for GCA.  Clin 
Ophthal, 2018  
This is the first description of nomograms for the diagnosis of 
GCA.  The length and location of the predictor lines on the 
Kattan nomogram graphically correlate with the magnitude of 
the odds ratio and p-value of each predictor in the logistic 
regression model.  The appropriate relative risk contribution 
of continuous versus binary variables is visually illustrated. 
Aids to statistics literacy for 
ophthalmologists.  Can J Ophthal, 
2016 
Lifelong learning necessitates the ability to independently 
synthesize the medical and scientific literature especially as 
machine learning algorithms become increasingly prominent 
in medicine.  This article pools the learning resources 
available to clinicians who want to learn and interpret 
statistics and supports the need for visual statistical aids such 
as nomograms. 
Support Vector Machines to predict 
TABx outcomes.  Can J Ophthal, 
2019  
In a meeting abstract, M. Lee et al (Lee et al., 2014) 
suggested that a GCA statistical model using support vector 
machines (SVM) had 100% classification accuracy.  Using 
our data (n=530) with proper tuning of the SVM did not show 
that SVM performed better than logistic regression. This 
appears to be the only published article detailing the 
application of an SVM model for the prediction of GCA. 
Neural network and logistic 
regression prediction models for 
GCA.  Clin Ophthal, 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This multivariable neural network and logistic regression 
prediction model builds on the framework of the primary 2017 
logistic regression (LR) paper, using the same 10 predictors.  
This even larger multicentre collaboration is the most 
comprehensive prediction model for GCA in the literature 
(n=1,201 complete cases).  Both internal medicine and 
ophthalmology patients were biopsied.  Missing data analysis 
and the stipulations of the transparent reporting guidelines 
(TRIPOD) were upheld.  
On multivariable LR age, platelets, jaw claudication, vision 
loss, log C-reactive protein, log erythrocyte sedimentation 
rate, headache, and clinical temporal artery abnormality were 
statistically significant predictors for GCA. Platelets were a 
stronger predictor for GCA than ESR or CRP. 
The AUROC /Hosmer-Lemeshow p-value for LR was 
0.867/0.119 vs NN 0.860/0.805, with no statistically 
significant difference (p=0.316). The misclassification 
rate/false-negative rate of LR was 20.6%/47.5% vs 
18.1%/30.5% for NN.  Decision analysis curves supported the 
utility of both models.   Missing data analysis did not change 
the results.  The neural network model had fewer false 
negatives than the logistic regression model.  Misclassification 
remains a concern, but the cut-off value for 99% sensitivity is 
provided (https://goo.gl/THCnuU).  The use of the NN-LR 
calculator may decrease the reliance on TABx for subjects at 
low risk for GCA.   
Only one other neural network for GCA has been published, 
(Astion et al., 1994) but it was developed from classification 
criteria and a database of known vasculitis patients, and did 
not include factors such as vision loss, C-reactive protein and 
platelets. 
DIAGNOSIS OF GCA:  TEMPORAL ARTERY BIOPSY 
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Systematic Review Yield of TABx 
for Suspected GCA.  Neuroophthal, 
2018 
 
This is the first systematic review of the utility rate (positive 
yield) of TABx in the literature and is registered on 
PROSPERO.  From 113 filtered articles, the median yield of 
25% with interquartile range (17%-34%) provides a 
benchmark for decisions regarding the under/overutilization of 
TABx and aids in the evaluation of non-invasive alternatives 
for the investigation of GCA such as ultrasound 
Local anaesthesia and anxiolytic 
techniques for oculoplastic surgery.  
Clin Ophthal, 2019 
TABx is performed under local anaesthetic.  This article 
reviews local anaesthetic techniques to facilitate oculoplastics 
procedures such as TABx.  It is one of the few articles that 
formally outlines anxiolytic techniques that can be used in 
conjunction with local anaesthesia. 
New oral anticoagulants and 
oculoplastic surgery. Can J Ophthal, 
2014 
Oculoplastics surgeons are the ophthalmologists who most 
frequently perform TABx.  In 2014, the direct oral 
anticoagulants (non-Vitamin K oral anticoagulants) were still 
emerging and had no antidote.  Our subspecialty was unsure 
how to deal with the many patients who were presenting for 
biopsies and surgery while on these medications.  This 
literature review co-authored with a prominent haemotologist 
was the first article to summarize the pre-operative 
considerations and pharmacology of the direct oral 
anticoagulants from an oculoplastic surgeon’s perspective. 
Practice Preferences: Temporal artery 
biopsy versus Doppler ultrasound in 
the work-up of giant cell arteritis.    J 
Neuro-Ophthalmology, Oct 2019 
 
 
     Although TABx has long been regarded as the gold 
standard confirmatory test for GCA, the 2018 EULAR 
guidelines and the 2020 revision from the BSR (drafted in 
2019) have suggested Doppler ultrasound (US) of the 
temporal arteries (+/- axillary arteries) as a possible alternative 
first-line investigation. 
     The preferred confirmatory test for GCA amongst 
ophthalmologists and neurologists was unknown.  Towards 
this end, an online survey of ophthalmologists, neurologists in 
North America, Europe and, Israel was conducted in summer 
2019; Canadian rheumatologists were also included.  There 
were 406 survey participants with an estimated survey 
response rate was 18%. To determine the survey margin of 
error, 95% confidence intervals were used.  Of the North 
American practitioners, 94.4 +/- 2.4% preferred TABx 
compared to 74+/-7.7% of their European physicians. Two per 
cent of North American practitioners preferred doppler 
ultrasound versus 24% of European physicians. Regional 
differences were statistically significant (p < 0.001).  There 
was no statistically significant difference in the proportion of 
ophthalmologists versus neurologists versus rheumatologists 
who preferred TABx  (p > 0.75). These results may aid in the 
future evaluation of preferred practice patterns. 
 
DIAGNOSIS:  DIFFERENTIAL DIAGNOSIS 
Overlap syndrome:  granulomatosis 
with polyangiitis and GCA, Can J 
Ophthal, 2013  
Patients with both GCA and granulomatosis with polyangiitis 
require more treatment than just glucocorticoids.  This 
uncommon case appears to be one of only 15 patients in the 
English literature with this constellation of findings. 
Systemic amyloidosis mimicking 
GCA.  Ophthalmic Surg Lasers, 1997  
Amyloidosis can present with many features that overlap with 
GCA including jaw claudication.  This uncommon entity has 
only been reported in fourteen other patients in the English 
medical literature. 
EPIDEMIOLOGY OF GCA 
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Incidence of GCA in Ontario, 
Canada. Can J Ophthal, 2019  
At the time of publication this was one of only two GCA 
incidence papers from Canada, and at the time of publication 
the sole study considering data from Ontario, which is 
Canada’s most populous province.  Dual calculation methods 
using pathology data from Kingston, Ontario as well as 
provincial billing data found the same cumulative annual 
incidence of biopsy-proven GCA at 4.9 per 100,000 
individuals aged 50 years or greater. 
Herpes zoster and GCA: a geo-
epidemiologic study.  Clin Ophthal, 
2018  
The role of herpes zoster in promoting GCA has been 
questioned.  This is the first ecologic analysis to examine the 
association in incidence rates between zoster and GCA in 
different countries.  The inverse relationship between the 
incidence rates of these two conditions reaffirms that zoster is 
unlikely to be the predominant immunopathogenic trigger for 
GCA. 
IMPACT  
Comments on Oh’s Bloodwork 
statistical prediction model for GCA.  
Int Med J, 2018 
This letter to the editor discusses Oh et al’s use of the full 
blood count as an ancillary test to support the diagnosis of 
GCA  (Oh, Wong, Andrici, et al., 2018).   Clinical symptoms 
such as jaw claudication and vision loss were not included.  
The importance of accurately reporting the number of patients 
(n=347 complete cases, versus n=537 with missing data) for a 
multivariable logistic regression model is stressed, as well as 
testing for multicollinearity testing given the multiple 
lymphocyte ratio analyses. 
Comments on Laskou's GCA 
probability score.  Clin Exp 
Rheumatol, 2019 
This letter to the editor critiques Laskou’s et al probability 
schema for GCA (n=122) (Laskou et al., 2019) with respect to 
i) overfitting given the small number of patients ii) the 
inaccurate assignment of arbitrary integer value risk scores to 
predictors of unequal importance or continuous variables, and 
iii) the value of  an online calculator in contrast to the 
botheration of adding Laskou’s 17 charted risk factors 
manually.   
Comment on Moraña, GCA and 
usefulness of a predictive calculator, 
Arch Soc Esp Oftalmol, 2019, 
accepted July 2019 
The authors contend that prediction models may decrease the 
need for TABx.  They suggest the use of the González-López 
logistic regression prediction model, but this requires the input 
of the temporal artery biopsy length.  Logistic regression 
requires complete-case analysis without missing data.  The 
NN-LR prediction models that calculate GCA risk prior to the 
TABx result are presented as a more practical alternative. 
Comment on Ross, Diplopia and 
GCA, J Neuro-Ophthal, 2019 
Ross et al published a case-control study on GCA and diplopia 
(n=27) in the Journal of Neuro-ophthalmology.  The data from 
our NN-LR prediction models provided an even larger cohort 
of GCA patients with diplopia (n=40).  We were able to more 
accurately contrast the characteristics of diplopia patients with 
positive versus negative TABx (instead of a case-control 
group) and emphasized that on multivariable analysis, 
diplopia is not a statistically significant predictor for GCA. 
Comment on Lyons et al, A new era 
of giant cell arteritis.  Eye, 2019.  
Online ahead of print Nov 25, 2019 
Lyons et al suggested that TABx was no longer the gold 
standard for the diagnosis of GCA.  In my correspondence I 
provided references for a meta-analysis and Bayesian analysis 
which both showed >=77% sensitivity of TABx.  The 
possibility of false-positive ultrasound, the advantages of 
tissue diagnosis for diseases that mimic the symptoms and 
signs of GCA, and the high initial cost of point-of-care 
ultrasound equipment was also discussed.   My comment on 
the suboptimal TABx from the TABUL study (7% missed 
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AAO = American Academy of Ophthalmology; BSR = British Society of Rheumatology; Can = Canadian; Clin = Clinical; EULAR = 
European League Against Rheumatism; GCA = giant cell arteritis; LR = logistic regression; NCT = non-contact tonometry; Opin = opinion; 
Ophthal = Ophthalmology; Sur = surgery; TABx = temporal artery biopsy; vs. =versus 
 
Chapter 3.  AUTHORSHIP CONTRIBUTION TO PUBLICATIONS 
     The doctoral candidate (DC):  
i) is first author of all the major publications, with estimated percentage contribution of at least 
95%  (see Table 5).    
biopsies, and 43% TABx less than 1 cm) was acknowledged 
by the authors who responded, “Sadly, this reflects routine 
care within the normal NHS practice”. 
Advances in the diagnosis of giant 
cell arteritis.  Current Opinion in 
Ophthalmology, Nov 2019, Vol 30, 
Issue 6. 
This invited paper to a top quartile ophthalmology journal 
summarizes some of the notable developments in GCA during 
the 18 months prior to June 2019.  Corneal oedema and 
proptosis from lacrimal gland ischemia are less common signs 
of GCA.  Drug-induced GCA from cancer treatment with 
immune checkpoint inhibitor therapy is mentioned.  The 
author’s study on decreased ocular pulse amplitude from DCT 
as an independent, statistically significant predictor for GCA 
is reviewed.  Transdermal optical coherence tomography and 
photoacoustic imaging are discussed as new imaging 
modalities for GCA.  The thesis prediction models are 
presented.  
CROSS-CUTTING PUBLICATIONS 
Neuro-ophthalmic History, Medscape 
Ophthalmology chapter, updated Nov 
2018 
 
 
 
The patient history and physical examination are the 
cornerstones of medical diagnosis.  These review chapters 
discuss many neuro-ophthalmic entities including giant cell 
arteritis, an eye disease that should never be missed.  These 
two medical chapters which have been updated biennially for 
the last two decades are part of the Medscape Ophthalmology 
library under WebMD.  “WebMD's network of websites is 
used by more unique visitors each month than any other 
leading private or government healthcare website, and is the 
leading health publisher in the United States.”  
https://bit.ly/2EFyBO6   
Neuro-ophthalmic Exam, Medscape 
Ophthalmology chapter, updated Jul 
2019 
The patient history and physical examination are the 
cornerstones of medical diagnosis.  These review chapters 
discuss many neuro-ophthalmic entities including giant cell 
arteritis, an eye disease that should never be missed.  These 
two medical chapters which have been updated biennially for 
the last two decades are part of the Medscape Ophthalmology 
library under WebMD.  “WebMD's network of websites is 
used by more unique visitors each month than any other 
leading private or government healthcare website, and is the 
leading health publisher in the United States.”  
https://bit.ly/2EFyBO6   
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ii) conceived and designed, acquired, analyzed and interpreted all the data for the publications.   
iii) obtained research ethics board (REB) approval for all the articles that required the same.   
iv) drafted and critically revised all the articles, and gave final approval of all the articles.   
v) is accountable for all aspects of the work and attest to its accuracy and integrity.   
vi) performed the primary statistical analysis of all the articles except for the support vector 
machines (SVM) article, where Dr Wanhua Su had to tune the SVM model using the R 
statistics package.   Royce Ing input the web programming and spreadsheet formulas to place 
the neural network and logistic regression calculators online. 
     There is one supporting publication where the DC is the senior responsible author but not 
the first author.  The DC’s estimated percentage contribution to the granulomatosis with 
polyangiitis case report is 60%.   
     The publications in this thesis have not been previously submitted for an award at an 
institute of Higher Education either in the UK or overseas.  See Appendix C (Form RD12a) 
Table 5. Estimated Contribution of Candidate to Each Publication 
ABBREVIATED ARTICLE TITLE (with clickable link) First 
Author 
Conception 
and Design 
Data 
Acquisition, 
Analysis, 
Interpretation 
Draft, 
Revision, 
Approval 
DIAGNOSIS OF GCA 
Multivariable prediction model for suspected GCA (Ing et al., 2017) 
Yes 100% 95% 95% 
Nomogram to Visually Interpret a Prediction Model for GCA.  Clin 
Ophthal (Ing and Ing, 2018) 
Yes 100% 100% 100% 
Support Vector Machines to predict TABx outcomes.  Can J Ophthal, (Ing, 
Su, et al., 2019) 
Yes 100% 65% 95% 
Neural network and logistic regression prediction models for GCA.  Clin 
Ophthal, (Ing, Miller, et al., 2019) 
Yes 100% 95% 95% 
Systematic Review Yield of TABx for Suspected GCA.  Neuroophthal, 
(Ing, Wang, et al., 2018) 
Yes 100% 95% 95% 
Local anaesthesia and anxiolytic techniques for oculoplastic surgery. Clin 
Ophthal, (Ing, Philteos et al., 2019) 
Yes 100% 100% 100% 
New oral anticoagulants and oculoplastic surgery. Can J Ophthal, (Ing & 
Douketis, 2014) 
Yes 100% 95% 90% 
Practice Preferences: Temporal Artery Biopsy versus Doppler Ultrasound in 
the Work-up of Giant Cell Arteritis. Neuroophthalmology, (Ing et al, 2019) 
Yes 100% 100% 90% 
Overlap syndrome:  granulomatosis with polyangiitis and GCA, Can J 
Ophthal, (Ong Tone, Godra and Ing, 2013) 
 
No 
 
100% 
 
95% 
 
60% 
Systemic amyloidosis mimicking GCA.  Ophthalmic Surg Lasers, (Ing et 
al., 1997) 
Yes 100% 100% 100% 
EPIDEMIOLOGY OF GCA 
Incidence of GCA in Ontario, Canada. Can J Ophthal, (Ing, Lahaie Luna, et 
al., 2019) 
Yes 100% 95% 95% 
Herpes zoster and GCA: a geo-epidemiologic study.  Clin Ophthal, (Ing, 
Ing, et al., 2018) 
Yes 100% 100% 100% 
IMPACT:  LETTERS TO EDITOR 
Bloodwork statistical prediction model for GCA.  Int Med J, (Ing, 2018) Yes 100% 100% 100% 
Comments on (Laskou's) GCA probability score.  Clin Exp Rheumatol, 
(Ing, Sambhi, et al., 2019) 
Yes 100% 100% 100% 
Comments on Moraña’s choice of a predictive calculator.  Arch Soc Esp 
Oftalmol, (Ing, 2019) 
Yes 100% 100% 100% 
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Diplopia and GCA, J Neuro-Ophthal, (Ing et al, 2019) Yes 100% 100% 100% 
Advances in the Diagnosis of GCA.  Current Opinion in Ophthalmology, 
(Ing et al, 2019) 
Yes 95% 95% 95% 
CROSS-CUTTING  AND SUPPORTING ARTICLES 
    
Neuro-ophthalmic History, emedicine chapter, updated Nov 2018 Yes 100% 100% 100% 
Neuro-ophthalmic Examination, emedicine chapter, updated Jul 2019 Yes 100% 100% 100% 
Lower OPA with DCT is associated with biopsy-proven GCA. Can J 
Ophthal, 2018 
Yes 100% 95% 100% 
DCT vs. NCT in Older Patients with Headache/Vision Loss.  Open Ophthal 
J, (Ing et al, 2018)  
Yes 100% 90% 95% 
Aids to statistics literacy for ophthalmologists.  Can J Ophthal, (Ing et al, 
2016) 
Yes 100% 100% 100% 
 
AAO = American Academy of Ophthalmology; DCT = dynamic contour tonometry; GCA = giant cell arteritis; LR = logistic regression; NCT 
= non-contact tonometry; OPA = ocular pulse amplitude; Ophthal = Ophthalmology; TABx = temporal artery biopsy; vs. =versus
 
Chapter 4. RESEARCH METHODOLOGY     
 
4.1 Overview, Data Collection and Classification (Prediction) Models 
 
     The method used to collect data for the prediction models and the pathology audit portion 
of the incidence study was a multicentre retrospective chart review.  The provincial billing 
data for the incidence study was obtained from the Ontario Medical Association database.   
The survey data was obtained prospectively using an online format.  The articles for the 
systematic review of temporal artery biopsy were obtained from online database and 
handsearch.  The methods used for data collection further summarized in Table 7.   REB 
approval was obtained for all studies requiring new/unpublished patient information.  All work 
was compliant with the Declaration of Helsinki.     
     The research was predominantly quantitative.  The published works span the evidence 
hierarchy of editorials, case reports, surveys, cross-sectional studies, cohort studies, systematic 
reviews and, meta-analyses.   
     The statistical programs used were Stata versions 14.2 and later 15.1 (StataCorp LP, 
College Station, TX, USA) and JMP Pro 13.2 (JMP, Marlow, Buckinghamshire, UK).  P-
values less than alpha 0.05 were regarded as statistically significant.   For the logistic 
regression and neural network prediction models, discrimination with receiver operating 
characteristic curves and calibration with Hosmer-Lemeshow and missing data analysis was 
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conducted.  Decision curve analysis was also performed for the neural network-logistic 
regression study.   
     The basic design of each publication, study size, and statistical analyses where applicable is 
summarized in Table 7 and further elaborated below.  GCA research collaborators were 
canvassed for at our Canadian national ophthalmic meetings, and with our online neuro-
ophthalmology and oculoplastics subspecialty groups.    
     The cynosures of this thesis are the multivariable diagnostic prediction models which were 
developed using three different supervised classification algorithms:  logistic regression (LR),  
support vector machine (SVM) and artificial neural networks (NN).  Linear regression and 
polynomial (quadratic) regression were not employed because our outcome variable was 
binary, i.e. “zero” for negative TABx versus “one” for positive TABx.  (Judd, McClelland and 
Ryan, 2017)  Linear regression assumes that the outcome variable is normally distributed, 
which is not the case with a binary dependent variable.  Also, if linear regression was used to 
model a binary outcome, there may be inappropriate predicted values outside of the range of 
(0,1) especially since our three bloodwork predictor variables were prone to outliers.  Finally, 
logistic regression allows disproportionate stratified random sampling on the dependent 
variable without biasing the coefficients (Allison, 2015).  In other words, the odds ratios of 
logistic regression are generalizable and do not depend on the prevalence of GCA in a 
particular geographic area.  Attempts to use quadratic terms in the logistic regression led to 
overfitting on the prediction response profile curves, and as such were avoided. 
     A systematic review found that when comparing clinical prediction models with low risk of 
bias, machine learning techniques such as SVM and NN may not have superior performance 
over LR with respect to the area under the receiver operating characteristic curve, but many of 
the articles examined had poor methodology especially with respect to calibration 
performance and validation procedures (Christodoulou et al., 2019).   We specifically 
examined each classification algorithm to determine if misclassification errors could be 
minimized especially the false-negative errors because a missed opportunity to prevent 
blindness is the costliest error in GCA.  Also, we applied a rigorous geographic external 
validation for our LR and NN models.  
     Binary logistic regression (LR) was utilized because it is the most common classification 
method used in medicine, (Dreiseitl and Ohno-Machado, 2002) and because the odds ratio can 
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aid statistical inference.  LR is useful for comprehending the influence of independent 
predictors on a single outcome but is sensitive outliers.  The probability for the outcome is 
estimated by fitting data on the logit function.   
     SVM was examined because a 2014 GCA study abstract with 182 patients reported 100% 
classification accuracy with SVM (Lee et al., 2014).  SVM represents the training data as 
points in space separated into categories by a gap (hyperplane) that is as wide as possible.  
When new cases are presented, they are mapped into the same space and categorized based on 
which side of the gap they are located.  However, SVM does not provide direct probability 
estimates, which require calculation using cross-validation.    
     NN was employed to try and decrease the number of false-negative errors from the logistic 
regression model. NN have building blocks or learning units, akin to neurons organized in 
layers, and share common roots in statistical pattern recognition with LR.  The neurons in a 
neural network are functions that transform input vectors into some output.  After input, the 
neurons in our model used a non-linear inverse tangent function to output to the next layer.  
During the training phase weightings are applied to signals passing from one unit to the next, 
and these weightings are optimized to adapt the neural network to the problem at hand. 
     We did not pursue random forest decision tree as a prediction model because its false-
negative rate was 82% using our data. 7                  
 
4.1.1 Logistic Regression and Neural Network Prediction Models 
 
     The 2019 NN and LR prediction model (n=1,201) is an extension of the P-LR (n=530) 
article.  The predictors collected for the NN-LR and P-LR models were the same, and the 
methodology for the larger LR model differs little from its predecessor.  For brevity, I only 
review the methodology of the NN and LR prediction models once and emphasize the largest 
and latest study (n=1,201 subjects with complete records out of 1,833 subjects who underwent 
consecutive TABx).  The methodology for the SVM model is discussed separately in a later 
section. 
     The GCA prediction model studies were approved by the Michael Garron Hospital REB and 
by the Institutional REB from each contributing centre.  Individual patient consent was not 
 
7 For comparison, the false negative rate of the logistic regression model was 47.5% and for the neural network 
model 30.5%.  See the Random forest decision tree section in the Supplementary Materials of the NN-LR article.  
https://docs.google.com/document/d/1kHVMxFmFDE-1UdSGMc65juD_h5Vd7mQCvAGR3s3bPJ4/edit   
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required as there was no patient randomization, there was no allocation to treatment groups, 
there were no new treatments, and because the study involved no more than record analysis, 
which was deidentified. The chart review was not blinded.  
     A retrospective chart audit of consecutive adult patients who had TABx for suspected GCA 
was conducted at 14 secondary and tertiary care medical centers in Canada (Toronto, ON; 
Kingston, ON; London, ON; Ottawa, ON; Hamilton, ON; Montreal, QC; Winnipeg, MB; 
Vancouver, BC), the United States (Baltimore, MD; Boston, MA; Rochester, MN; Fisherville, 
VA; and Tampa, FL), and Zurich, Switzerland.    The outcome variable for the prediction models 
was biopsy-proven GCA, i.e., the pathologic diagnosis from TABx was considered the final 
diagnosis.  Indeterminate TABx were regarded as negative TABx. Healed arteritis was 
considered a positive TABx if glucocorticoid improved the patient’s symptoms, and long-term 
steroid treatment was prescribed.  The inclusion of healed arteritis in our group of positive 
biopsy results requires a caveat.  There are no absolute histopathological features that 
distinguish healed arteritis from changes due to atherosclerosis, arteriosclerosis, or trauma (often 
referred to as “healed arterial injury”).  Indeed, in a study of the interobserver variability in the 
histopathologic diagnosis of giant cell arteritis, the category of healed arteritis had the greatest 
interobserver variability (up to 50%) (McDonnell et al., 1986).  The interpretation of this result 
as representing healed arteritis is a clinic-pathologic decision made in conjunction with the 
clinical response to glucocorticoids and serological features of each individual patient. Most 
studies do not specify the diagnostic criteria used to qualify a case as healed arteritis, but as this 
diagnosis results in treatment, this was included as a positive biopsy. 
     The predictor variables were chosen from clinical judgment, the results of a prior pilot study 
(Ing, Pagnoux, et al., 2018) and literature including the 1990 ACR classification criteria for 
GCA (Hunder et al., 1990).  The predictor variables were age, gender, new-onset headache 
(HA), clinical temporal artery abnormality (TAabn), jaw claudication (JC), permanent retinal, 
optic nerve or visual pathway ischemic vision loss (VL), diplopia, pre-steroid erythrocyte 
sedimentation rate (ESR), pre-steroid C-reactive protein (CRP) divided by the upper limit of 
normal (for vasculitis) for each lab, and pre-steroid platelet level. For this study, VL was 
interpreted as decrement in prior acuity not explained by refractive error or media opacity, 
fundus abnormality (e.g. nerve fibre layer infarct, disc oedema, CRVO) visual field loss or a 
relative afferent pupillary defect.  
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The dose and duration of glucocorticoid treatment prior to TABx was recorded, as was the 
length of the biopsy. Because our endpoint was biopsy-proven GCA, subjects who did not have 
TABx within 2 weeks of glucocorticoid initiation were excluded. TABx may remain positive 
for 2–6 weeks after commencement of treatment (Dasgupta et al., 2010) but the 2-week cut-off 
was chosen to minimize the chances of false-negative pathology, and because the histologic 
findings of GCA may begin to alter only after 4 days of glucocorticoid treatment (Font and 
Prabhakaran, 2007). Bloodwork values that were not obtained prior to glucocorticoid initiation 
were not used for analysis, but patients were still considered for the missing data analysis 
(MDA). In patients who had bilateral TABx, the sum of the biopsy lengths was recorded as the 
biopsy length.  
Polymyalgia rheumatica (PMR) was not included as a predictor variable as it can be a nonspe-
cific clinical manifestation, with overlapping age and acute phase response characteristics with 
GCA. The distinction of PMR from osteoarthritis flare can be difficult; reports of joint X-rays 
were not uniformly available in this study.  Also, rotator cuff injury and fibromyalgia may have 
overlapping clinical features with PMR. El-Dairi’s study did not find that PMR was a 
statistically significant predictor for a positive TABx (El-Dairi et al., 2015). 
Race/ethnicity was excluded as a study variable because it can be difficult to define and is an 
indeterminate proxy for genetic similarity. Many scholars view racial identity as primarily a 
social construct and one that can misdirect the categorization of participants in biomedical 
research. In addition, many of our charts did not identify ethnicity or race. Using the internal 
biologic effect of an individual study participant’s self-reported race/ethnicity is thought to have 
low potential validity in observational research (Kaufman and Cooper, 2001).   Although GCA 
may be rare in China and Japan, a recent U.S. study found similar rates of GCA in blacks and 
whites (Gruener et al., 2019). 
Our minimum required sample size was 600 patients, to allow for 100 events and 200 non-
events in each of the development and validation sets, as recommended for external validation 
of LR prediction rules (Vergouwe et al., 2005).  A formal sample size calculation for an NN is 
exceedingly difficult to make. Our aim was to acquire at least 1,000 subjects for an NN, to 
facilitate the development training, validation, and test (holdout) sets. Internal validation and 
geographic external validation were performed for the neural network and logistic regression 
models.  
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The individual patient was the unit of analysis for the statistical models. Statistical 
evaluations were performed using Stata 14.2 - 15.1 (StataCorp LLC, College Station, TX, USA), 
JMP Pro13.2 (JMP SAS Institute, Marlow, Buckinghamshire, UK), and R 3.5.0 (R Foundation 
for Statistical Computing, 2018, Vienna, Austria). An α=0.05 was used for statistical 
significance.  
The continuous variables were graphed. Histogram of the CRP and ESR data showed a right 
skew distribution, but the distribution of the platelets was approximately normal.  A logarithmic 
transform was used to normalize the CRP and ESR and improve the LR model. For the NN, the   
“transform covariates” option (Johnson distribution) in JMP Pro was selected for the continuous 
variables. 
Tests for multicollinearity were performed.  The LR model had no model misspecification 
and no multicollinearity, with a mean variance inflation factor 1.17, and the variance inflation 
factors for ESR, CRP, and platelets were 1.42, 1.54, and 1.18, respectively.  
     The NN was designed in JMP Pro 13.2 with a single hidden layer and the hyperbolic tangent 
activation function Figure 7. The number of nodes in the hidden layer was determined from a 
preliminary analysis of the minimum root mean square error (RMSE) (Duke Fuqua, 2007) of 
models with one to nine nodes in the hidden layer; four nodes provided the lowest RMSE. To 
fit the NN, we transformed covariates, used the absolute penalty method, and performed 20 runs. 
Continuous variables were transformed using the Johnson distribution to minimize the negative 
effects of outliers or highly skewed distributions. The absolute penalty method further decreased 
the chance of overfitting and was chosen over the squared penalty method because our previous 
P-LR analysis had shown that the ten input variables had unequal predictive ability. The 20 runs 
(designated as tours in JMP Pro) mitigate the issue with local minimums.  The NN analysis with 
one hidden layer, four hidden units, transformed covariates and squared penalty method was run 
25 times. The NN with the least number of FNs was chosen as the final model.  
     Internal validation using tenfold cross-validation was performed. For the LR, the c-statistic 
was averaged for each fold with bootstrapping of the cross-validated area under the curve 
(Luque-Fernandez, Maringe and Nelson, 2017). Tenfold cross-validation was also performed 
for the NN using JMP Pro for internal validation with a random seed of zero.  
     Instead of using a holdout set with the same probability distribution as the training set, 
external validation by geographic study site was used as a more rigorous evaluation of the 
generalizability our prediction models.  External validation by geographic site simulated the 
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real-world situation of a prediction model developed in one region, being tested in a new 
environment.  To facilitate geographic external validation, the data from each contributing 
centre was maintained clustered.  The cluster LR was performed with the same training set 
(n=1,181) data partition as the NN model.  For the NN the validation set had 311 subjects and 
the holdout (test) set had 341 subjects.  Subjects in the holdout set were from the geographic 
centres located the furthest from Toronto, Canada which included British Columbia, 
Switzerland, or the sites most culturally disparate i.e. Quebec and Switzerland.  Model 
performance was reported for discrimination, calibration, and clinical utility. Receiver operating 
characteristic curves (ROC) analysis and c-statistic was performed in JMP Pro to determine the 
discrimination of each model. Calibration was performed with the Hosmer–Lemeshow test and 
calibration plots using Stata. Overall performance measures were reported using the Brier score 
and generalized R2. The clinical utility of the models was determined with decision curve 
analysis (DCA).   
     DCA uses a net benefit approach that incorporates “benefits” (true positives) and “harms” 
(false positives) weighting the latter to reflect relative clinical consequences i.e. to determine 
whether basing clinical decisions on a model would do more good than harm (Vickers and Elkin, 
2006). With DCA, the strategy with the highest net benefit (true positive) at a particular 
threshold probability has the highest clinical value (Vickers and Elkin, 2006). The threshold 
probability (Pt) on the x-axis is the probability where the expected benefit of performing TABx 
is equal to the expected benefit of avoiding TABx i.e. the minimum probability of GCA at which 
the patient will opt for TABx. For our DCA, we assumed there was no harm in performing a 
TABx, although it is invasive with risks of facial nerve palsy, infection, and bleeding. TABx is 
also time-consuming and incurs a moderate expense. DCA showed that both the LR and NN 
models had clinical utility for a wide range of threshold probabilities (Pt). Both models were 
equivalent or better than a “biopsy-all strategy” for all Pt, and superior to a “biopsy none” 
strategy up to Pt,0.81 (See bottom of Table 6). 
MDA was performed with the “informative missing” option in JMP Pro for LR and NN using 
mean imputation for continuous effects. For categorical effects, the missing value was coded as 
a separate level of the effect. Multiple imputation (MI) with chained equations with 30 
imputations was performed using Stata for the LR and R for the NN. Stata does not perform NN 
analysis.  Further methodology details are found in the supplementary materials for the article 
in the link below.  
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Table 6. Comparison of Model Performance.  Logistic Regression versus Neural Network 
with complete case analysis and missing data analysis by mean imputation on the test 
(holdout) set. 
 
 
 
4.1.2 Nomogram 
 
Kattan nomograms for logistic regression equations can be constructed in Stata by entering the 
command “nomolog” after the logistic regression has run. Nomolog is a Stata plug-in (Zlotnik 
and Santos, 2013). 
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4.1.3 Support Vector Machines Model 
 
     The methodology for the SVM prediction model (n=530) varied slightly from the LR and 
NN models, although the model employed the same 10 predictor variables (age, sex, temporal 
artery tenderness or decreased pulsatility, new-onset headache, vision loss, diplopia, jaw 
claudication, platelet level, log of the erythrocyte sedimentation rate (ESR), and log of the C-
reactive protein (CRP)  and outcome (temporal artery biopsy result).   Although logistic 
regression can process skewed data, the logistic regression model was more accurate when the 
ESR and CRP data were normalized via log transformation. We maintained the log 
transformation to compare the logistic regression and SVM models. Age and bloodwork were 
maintained as continuous variables.   My statistician co-author Dr Wanhua Su used the R 
statistics package (version 3.4.2, http://www.R-project.org/) to compare logistic regression and 
SVM.   The dataset of 530 subjects was randomly split into training and test sets. The resulting 
training set had 210 subjects with negative TABx and 70 subjects with positive TABx. The 
test set had 187 negative TABx and 63 positive TABx. Models were fit on the training set and 
their performance compared on the test set. The area under the receiving operating curve 
(AUC), average precision (AP), misclassification rate (MCR), and false-negative rate (FN) 
were determined for each model. The SVM model with a radial basis function kernel was 
further tuned examining both the AUC and MCR with 5-fold cross-validation to determine the 
optimum ɣ and cost (c) parameters. The logistic regression and SVM receiver operating 
characteristic (ROC) curves were compared with DeLong’s test for 2 correlated ROC curves 
(DeLong, DeLong and Clarke-Pearson, 1988) and the statistical package (pROC) (Robin et 
al., 2011). 
     For our dataset, the SVM model with optimal discrimination had gamma= 0.01267 and cost 
= 26.466, with 133 support vectors.  DeLong’s test showed no statistically significant 
difference between the logistic regression and SVM ROC curves (z = 0.16621, p = 0.868) with 
almost overlapping ROC curves  (see Figure 13).  However, the SVM model had a 5% higher 
false-negative rate than LR and in GCA false-negative errors are the greatest concern with 
GCA.  Given the increased difficulty in tuning and interpreting SVM results compared to LR, 
SVM did not offer any distinct advantage over LR in our dataset of 530 TABx subjects. 
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Figure 13. ROC analysis of logistic regression and optimized support vector machine 
predictive models.  
 
The discrimination of the logistic regression and support vector machine models are almost 
identical. Logistic = logistic regression; SVM= support vector 
 
 
4.2 Systematic Review of the Yield of Temporal Artery Biopsy for Suspected GCA 
 
The systematic review was registered on the International Prospective Register of Systematic 
Reviews (PROSPERO) ID=CRD42017078508.   
     Relevant articles were sourced from PubMed, Embase, Cochrane Central Register of 
Controlled Trials, Google Scholar, Open Grey, and hand search from 1 January 1998 to 31 
December 2017, using the search terms (“giant cell arteritis OR temporal arteritis”) AND 
“biopsy”.  Studies were excluded if they reported patients with positive TAB only or patients 
with negative TAB only, or if only patients with an established clinical diagnosis of GCA 
were selected.  Four thousand three hundred and fifty-nine GCA studies were identified and 
after review 113 remaining articles were included for meta-analysis.   (see Figure 14, PRISMA 
diagram)  
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Figure 14. Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) 
Flow Diagram for Meta-analysis of Yield of Temporal Artery Biopsy 
 
 
 
Five authors elected eligible studies and performed the quality analysis (DW, EB, JM, AK, 
and GS). Disagreements were adjudicated by the principal author (EI).  The quality analysis 
was performed from the perspective of the potential for bias in the TABx results.  
     The major criteria for selection bias were non-consecutive TABx in the study group and 
verification bias. Although articles investigating ultrasound/magnetic resonance imaging 
(MRI) for GCA may have had little bias with respect to the imaging investigation, TABx may 
not have been obtained in all patients, or the decision to perform TABx may have been 
influenced by the result of the imaging study, leading to verification bias. In a large TABx 
series of unilateral and bilateral biopsies, if only results of the bilateral biopsies were reported 
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this was considered selection bias. If only subjects with high ACR scores underwent TABx, 
this was considered a possible performance bias. If the pathologist was not blinded to the 
patient’s symptoms, bloodwork results, or ACR score, this was a possible detection bias. 
Withdrawals from TABx (e.g. patient refusal to undergo TABx, or a vein or nerve specimen 
rather than the artery) were considered an attrition bias. If the pathology results from all 
patients that underwent TABx were not listed, this was considered a reporting bias. The main 
reason for “other bias” was because TABx series from the same city, author, or institution 
had a partial overlap of patients that we could not eliminate.   
     The 113 articles encompassed 30,898 TABx, of which 7379 (23.9%) were positive. The 
yield of TABx from the articles had a right skew distribution with a non-weighted mean 
27.7%, and median 25.0% with interquartile range 17% to 34%. 
 
Figure 15. Histogram of the Yield of Temporal Artery Biopsy from 113 Studies 
                          
 
Initial analysis was performed with Stata 14.2 (StataCorp LLC, College Station, TX, USA) 
using a random-effects meta-analysis of proportions (metaprop) with Freeman–Tukey double 
arcsine transformation to stabilize the variances and exact confidence intervals (Nyaga, Arbyn 
and Aerts, 2017).  Stata was used to perform a random effects meta-regression of the 
aggregate-level data (metareg). If heterogeneity exceeded 75%, we would also compare the 
results with MetaXL 5.3 (EpiGear International Pty Ltd) fixed-effect inverse variance 
heterogeneity model (IVHet) with double arcsine prevalence transformation, 0.5 continuity 
correction, and normalized prevalence (Doi et al., 2015).  If heterogeneity exceeded 90%, we 
would report the median yield and interquartile range.  When available, the pre-specified 
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predictors of patient age, proportion of females, specimen length, bilateral TABx, ACR scores 
greater than or equal to three, vision symptoms, duration of steroid use prior to TABx, study 
size, decade of study, and use of arterial imaging (ultrasound or MRI) were recorded from 
each study for metaregression. A p-value < 0.05 was considered statistically significant. The 
utility rate of TABx by country and yield from first decade versus second decade of reports 
were also compared.  The I2 statistic of 92% suggested that heterogeneity was too large to 
perform meta-analysis.  As such the median and interquartile range were reported.  
Notwithstanding metagression was performed.  On univariate metaregression, age was the 
only statistically significant patient factor associated with TABx yield (see Figure 16). 
 
Figure 16. Random effects metaregression of the yield of temporal artery biopsy versus age 
                            
 
4.3 Incidence of GCA in Ontario 
     Kingston, Ontario, Canada has a prominent medical centre (Queens University) that is 
relatively isolated from other medical facilities.  The incidence study was approved by the 
REBs at Michael Garron Hospital and at Queens University and compliant with the 
Declaration of Helsinki.  In Kingston, ON TABx were only performed at two medical 
facilities and there was a well-contained catchment area as the next closest surgical centre was 
at least 100 kilometres away.  Thus, most if not all the cases of biopsy-proven GCA from 
Kingston would be captured.  A chart review for all TABx cases from the Kingston hospitals 
(Kingston General Hospital and Hotel Dieu Hospitals) was completed for the 48-month period 
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from October 2011 to September 2015 inclusive. Only patients with residence postal codes 
within the federal electoral districts of Kingston and the Islands, and the adjoining districts of 
Leeds-Grenville Lanark-Frontenac, and Hastings-Lennox and Addington were included in this 
study.    The population of the Kingston catchment area was calculated by averaging the data 
from the 2011 and 2016 Canada Census data (Government of Canada, 2019).  Because GCA 
rarely is seen before the 6th decade of life, only individuals 50 years of age and over were 
tabulated in each electoral district for the population denominator.  A query to the private 
pathology labs (Life Labs-CML and Dynacare) and the Quinte Health System was also made 
to see if any patients with Kingston postal codes had TABx submitted outside of the Kingston 
hospital system. In the second part of this study, we used the 2016 Canada census data, 
provincial billing data, and a meta-analysis of the positive yield of TABx series performed in 
Ontario to estimate the incidence of GCA in Ontario, Canada.  The Ontario billing code for 
TABx is Z815A, but there was no accompanying pathology database that identified positive 
versus negative biopsies.  To estimate the incidence of biopsy-proven GCA in Ontario, we 
determined the number of patients who underwent TABx (code Z815A) from July 1, 2015, to 
June 30, 2017.  The population denominator of Ontarians 50 years of age or older was 
tabulated from the 2016 Canada Census Profile.  The expected positive yield (utility rate) of 
TABx for our province was calculated from review of the Ontario TABx series  in the 
literature, Kingston data, and a Toronto hospital pathology audit (D. Munoz, personal 
communication, TABx pathology service audit 2012–2017, St. Michael’s Hospital, Toronto, 
2017).  All published English language articles on GCA and TABx were reviewed from 1981–
2017 and studies performed in Ontario, Canada were retained.   
     For the pathology audit, the population denominator at risk was ascertained using the postal 
codes of patients with biopsy-proven GCA from Kingston and the corresponding population 
denominator listed in the Canada census federal electoral district data at the time the TABx 
were performed.  This self-contrived temporal geocoding technique is relatively simple, but has 
not been documented on Google Scholar and Pubmed literature search.  Averaging the figures 
between the 2011 and 2016 Canada census data, the population of individuals 50 years of age 
or older with postal codes corresponding to the Kingston catchment area yielded the 
population denominator of 179,503 individuals.  During the 4-year study period, 176 patients 
underwent TABx in Kingston, and 36 had biopsy-proven GCA.  One subject with biopsy-
proven GCA resided in the Northumberland-Pine Ridge federal electoral district and was 
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excluded from the analysis. From a pathology audit of temporal artery biopsies (TABx) in 
Kingston, ON, and federal census data, the minimum cumulative annual incidence of biopsy-
proven GCA was 4.9 per 100,000 individuals over the age of 50 years.   
     Ontario, Canada has universal health care with a single party provincial payer, but it does 
not have a centralized registry or database for GCA or the results of TABx.  Provincial billing 
data for the number of TABx performed is available.  For billing purposes, rheumatologists in 
Ontario code cases of GCA using the 3-digit International Statistical Classification of 
Diseases, Ninth Edition (ICD-9) diagnostic codes as either code 446 “polyarteritis nodosa and 
allied conditions” or code 447 “other disorders of the arteries and arterioles.” The Ontario 
billing system does not use the more specific ICD-9 four-digit code for GCA, which is 446.5.  
This makes it difficult to separate GCA from other vasculitides with billing data.  
Furthermore, ophthalmologists may code their patients with GCA as primary ophthalmic 
disorders using ICD-9 codes such as optic neuropathy.   All patients undergoing TABx 
procedures (Z815A) who were billed were identified, but there was no pathology database that 
identified which biopsies were positive.  As such, we derived the expected positive yield of 
TABx from the meta-analysis of 5 series of TABx performed in Ontario, Canada.   Statistical 
analysis was performed with Stata 14.2 (StataCorp LLC, College Station, TX) using a meta-
analysis of proportions (metaprop) with a random effects analysis.  Random effects meta-
analysis of the five Ontario series of TABx from Toronto, ON (Ing, Pagnoux, et al., 2018) (D. 
Munoz, personal communication), Ottawa, ON, (Ing et al., 2017)  Hamilton, ON, (Rhéaume et 
al., 2017)  and Kingston, ON.(the present study) found the positive yield of TABx in Ontario 
to be 0.21 (95% CI0.18–0.24) with I2 13.1% ( 
 
 
 
 
 
 
Figure 17) 
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Figure 17. Random effects meta-analysis of the positive yield of temporal artery biopsy in 
Ontario, Canada. 
 
The pooled estimate for the utility rate of temporal artery biopsy in Ontario, Canada was 
21%. 
     In part due to skip lesions or false-negative TABx, the use of BPGCA to determine 
incidence may underestimate the number of cases of GCA compared with studies that also 
include clinically diagnosed GCA.  The diagnosis of BPGCA relies on properly performed 
surgery with, adequate length specimens that also are appropriately interpreted by the 
pathologist. 
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4.4 Practice Preference Survey: Temporal Artery Biopsy versus Doppler Ultrasound in 
the Work-up of Giant Cell Arteritis 
 An REB-approved online survey of ophthalmologists and neurologists in North 
America, Europe and, Israel was conducted in May and June 2019.  Canadian rheumatologists 
were also canvassed.  
The survey instrument was Survey Planet, (https://surveyplanet.com/). The three study 
questions were: 1) What test do you currently use to confirm the diagnosis of giant cell arteritis? 
2) Where do you work? and 3) What is your primary speciality? The available responses to each 
question are shown in Appendix D and at https://s.surveyplanet.com/UJ2kjVmw6.  The survey 
did not advance until all questions were answered, and the software prevented double entries 
from the same computer or internet protocol (IP) address.  
Practitioners with membership in neuro-ophthalmology (European Neuro-
ophthalmology Society, North American Neuro-ophthalmology Society) and oculoplastic 
surgery societies (American Society of Oculoplastic and Reconstructive Surgery, Canadian 
Society of Oculoplastic and Reconstructive Surgery) were targeted as these specialists were 
most likely to encounter patients with GCA.  The survey was also sent to a group of Canadian 
rheumatologists from Ontario, Canada. To optimize the response rate, the survey was kept 
anonymous, designed to be completed in 25 seconds, incorporated a logo, avoided questions 
about age or years in practice (Fan and Zheng, 2010).  Also, on the internet lines that allowed 
mass emailing, requests for survey responses were canvassed at least twice on two separate 
dates.  Respondents could free text additional details, and their email address if they desired. 
The results of the European and Israeli physicians were pooled as a group.   
The survey margin of error was determined from the survey sample size, the percentage 
of the sample that chose a particular answer, and the estimated population size using the 
calculator from https://www.surveysystem.com/sscalc.htm.  The margin of error was reported 
as a 95% confidence interval.  Two-sample tests of proportions were used to compare regional 
and practice speciality preferences. 
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4.5 Geoepidemiologic Analysis of Incidence Rates:  Zoster versus GCA 
 
The IRGCA was searched for on PubMed, Embase, and Google Scholar from inception to July 1, 
2017, using the search terms: incidence, epidemiology, country, temporal arteritis and GCA. 
The same search was repeated using herpes zoster in place of the arteritis terms. 
The country-specific IRs for subjects 50 years of age and older were recorded per 100,000 
population for GCA, and per 1,000 person-years for HZ. If IRs were provided for multiple years, 
the results were averaged. 
The IRGCA in Japan was calculated using Koboyashi’s reported prevalence rate of 1.47 per 
100,000 in subjects aged 50 years or older, with the average age of onset of 71.5 years 
(Kobayashi et al., 2003).  Lifespan is thought not to be affected by GCA unless the patient has 
aortic aneurysm or dissection (Kermani et al., 2013).  The average life expectancy in Japan is 
83.3 years (United Nations, 2015). As GCA is a rare disease and recurrent, the IR was estimated 
as the prevalence rate/duration of disease =1.3 per million subjects 50 years or older. 
Because the peak onset of GCA is in the 8th decade (Gonzalez-Gay et al., 2010), we also 
examined the IR of HZ in 70-year-olds. If the age brackets straddled our chosen age cut-offs, 
the IR values from the two adjacent brackets were averaged. Only countries/regions that had 
IRs available for both GCA and HZ were used for analysis. Paired t-test was used to examine 
the time difference in year of publication between the GCA and HZ studies for each country. 
There was inadequate information in the GCA articles to consistently calculate the within-study 
standard errors needed for meta-regression. Pearson product-moment correlation coefficients 
and linear regression with and without robust standard errors were performed. White’s test was 
used to test for heteroscedasticity. All statistical tests were conducted with Stata 14.2 (StataCorp 
LP, College Station, TX, USA), and a two-sided p<0.05 was considered statistically significant. 
     Apart from Olmsted County and the United Kingdom, the availability of IRGCA and IRHZ 
from the same time frame and corresponding geographic region was limited. Eight of the 14 
countries (57%) (see Appendix E) were overlapping in the time frame of the corresponding 
GCA and HZ studies. On paired t-test, the GCA studies were published on average 4.5 years 
before the HZ studies (p=0.09). A published IRGCA for Iceland was available. The IRHZ for 
Iceland was only available for the 60-year age group only (4.7 per 1,000), but not the 50-year-
old or 70-year-old age groups, and as such was not used. 
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     Pearson product-moment correlation coefficient (r) comparing IRGCA with: IRHZ in 50-
year-olds was -0.51 (p=0.07), and IRHZ in 70-year-olds was -0.40 (p=0.16). Linear regression 
with robust standard errors showed a regression coefficient (β) -2.92 (95% CI -5.41, -0.43; 
p=0.025) between the IRGCA 50-year-olds, and the IRHZ in 50-year-olds. For the IRHZ in 70-
year-olds, no statistically significant linear dependence of the mean IRGCA on IRHZ was 
detected (β=-1.78, 95% CI -4.10, 0.53; p=0.12). White’s test did not suggest 
heteroscedasticity.  Subgroup regression analyses of the per-country IRGCA and IRHZ, with and 
without overlapping timeframes were not statistically significant and did not show a positive 
regression coefficient. 
When the incidence of GCA and zoster was replotted with a local polynomial smoothed line 
and 95% confidence interval, no consistent biologic gradient between the incidence rates of 
GCA and zoster was seen. 
Figure 18. Incidence rate of GCA versus Zoster in subjects greater than age 50 years per 
country with a local polynomial smoothed line and 95% confidence interval. 
 
 
                
Table 7. Summary of Methodology Used in Each Publication 
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ABBREVIATED PUBLICATION 
TITLE           (with clickable link) 
METHODOLOGY Study design, n= number of 
subjects                       Statistics [Statistics Program] 
DIAGNOSIS OF GCA:  STATISTICAL PREDICTION MODELS 
Multivariable prediction model for 
suspected GCA.   2017   (P-LR) 
Retrospective chart review cohort study at 7 medical 
centres (n = 530 complete cases).  TRIPOD-compliant 
CRP and ESR were right-skewed and therefore log-
transformed 
Logistic Regression 
Internal Validation (10-fold cross-validation and 
bootstrap)  
External Validation (geographic holdout) 
[Stata 14.2, JMP Pro 13.2] 
Nomogram to Visually Interpret a 
Prediction Model for GCA.  Clin Ophthal, 
2018 
In Stata the “nomolog” command was entered after 
logistic regression (n=530) 
Logistic regression, Kattan Nomogram [Stata 14.2] 
Aids to statistics literacy for 
ophthalmologists.  Can J Ophthal, 2016 
Review and Summary of Literature 
Support Vector Machines to predict TABx 
outcomes.  Can J Ophthal, 2019  
Data from the P-LR multicentre retrospective chart 
review (n=530 complete cases).  A training set was tuned 
with radial basis kernel function.  ROC of SVM and LR 
models were compared. 
Support Vector Machines, Logistic Regression, 
DeLong’s test [Stata 14.2 and R] 
Neural network and Logistic Regression 
prediction models for GCA.  Clin Ophthal, 
2019 
Retrospective chart review cohort study from 14 
international medical centres (n = 1,201 complete cases). 
TRIPOD-compliant.  The 10 predictor variables from the 
P-LR model were retained. 
Logistic Regression:  clustered by centre, ESR and CRP 
were log-transformed 
Neural Network:  one hidden layer with 4 nodes, ESR 
and CRP had Johnson transformation 
Internal Validation (10-fold cross-validation and 
bootstrap) 
External Validation (geographic holdout) 
Decision Analysis Curves to verify utility of the model 
 [Stata 15.1, JMP Pro 13.2] 
DIAGNOSIS OF GCA:  TEMPORAL ARTERY BIOPSY 
Systematic Review Yield of TABx for 
Suspected GCA.  Neuroophthal, 2018 
Systematic review of the literature (n = 113 articles)  Relevant 
articles were sourced from PubMed, Embase, Cochrane Central 
Register of Controlled Trials, Google Scholar, Open Grey, and 
hand search from 1 January 1998 to 31 December 2017, using 
the search terms (“giant cell arteritis OR temporal arteritis”) 
AND “biopsy”.  The study was registered on PROSPERO. 
Random effects Meta-analysis of Proportions and Meta-
Regression [Stata 14.2] 
Local anaesthesia and anxiolytic 
techniques for oculoplastic surgery.  Clin 
Ophthal, 2019 
Literature review 
New oral anticoagulants and oculoplastic 
surgery. Can J Ophthal, 2014 
Literature review 
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Practice Preferences: Temporal Artery 
Biopsy versus Doppler Ultrasound in the 
Work-up of Giant Cell Arteritis 
Online survey instrument:  Survey Planet  
https://s.surveyplanet.com/UJ2kjVmw6 
The ophthalmology and neuro-ophthalmology speciality 
societies in North America and Europe and the Canadian 
Rheumatology society were canvassed by email as these 
were the specialists most likely to encounter GCA.  We 
did not receive any responses from EULAR.  Where 
possible, the techniques described by Fan and Zheng 
were used to optimize survey response. 
 
Survey margin of error (95% confidence intervals) 
https://www.surveysystem.com/sscalc.htm 
 
Two sample tests of proportions [Stata 14.2] 
DIAGNOSIS OF GCA:  Differential Diagnosis 
Overlap syndrome:  granulomatosis with 
polyangiitis and GCA, Can J Ophthal, 
2013 
Case Report, Review of literature 
Systemic amyloidosis mimicking GCA.  
Ophthalmic Surg Lasers, 1997  
Case Report, Review of Literature 
EPIDEMIOLOGY OF GCA 
Incidence of GCA in Ontario, Canada. Can 
J Ophthal, 2019  
Cross-sectional study to determine incidence of GCA.  
Dual methods employed: 
1) Retrospective pathology audit, Kingston, ON with 
postal code information to geocode population 
denominators in the Canada Census (n=172) 
2) Provincial Billing Data to determine number of 
patients undergoing TABx (n=2,404) along with random 
effects 
Meta-analysis of TABx yield from Ontario, CA studies, 
Incidence estimate with 95% confidence interval [Stata 
14.2] 
Herpes zoster and GCA: a geo-
epidemiologic study.  Clin Ophthal, 2018  
Ecological study with geographic comparison of the 
incidence rates of herpes zoster and GCA from literature 
review (“n” =14 countries) 
Linear regression, Pearson product motion correlation 
t-test analysis of incidence rates from different time 
periods versus same time period [Stata 14.2] 
IMPACT  
Bloodwork statistical prediction model for 
GCA.  Int Med J, 2018 
Letter to the Editor, Critique of Literature 
Comments on (Laskou's) GCA probability 
score.  Clin Exp Rheumatol, 2019 
Letter to the Editor, Critique of Literature 
Comments on Moraña, Arch Soc Esp 
Oftalmol 
Letter to the Editor, Critique of Literature 
Diplopia and GCA, J Neuro-Ophthal, 2019 Letter to the Editor, Critique of Literature,  
Logistic Regression [Stata 14.2] 
CROSS-CUTTING OR SUPPORTING ARTICLES 
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Neuro-ophthalmic History, emedicine 
chapter, updated Nov 2018 
Literature review 
Neuro-ophthalmic Exam, emedicine 
chapter, updated Jul 2019 
Literature review 
DCT versus NCT in Older Patients with 
Headache/Vision Loss.  Open Ophthal J, 
2018 
Prospective Cohort study, Single Centre (n=106) 
Bland Altman plots [Stata 14.2] 
Lower OPA with DCT is associated with 
biopsy-proven GCA. Can J Ophthal, 2018 
Prospective validation study, Single Centre (n= 109 
complete cases) Logistic regression [Stata 14.2] 
 
AAO = American Academy of Ophthalmology; DCT = dynamic contour tonometry; GCA = giant cell arteritis; LR = logistic 
regression; NCT = non-contact tonometry; ON = Ontario; OPA = ocular pulse amplitude; Ophthal = Ophthalmology; TABx = 
temporal artery biopsy; TRIPOD = compliance with guidelines for transparent reporting of multivariable prediction models 
for individual prognosis and diagnosis, with missing data analysis 
 
Chapter 5.  IMPACT 
       The impact of the doctoral research is presented in the categories of: 
i) Clinical impact 
ii) conference presentations 
iii) professional networks, teaching opportunities and award nominations 
iv) publication metrics and literature citations  
v) invited paper and requested article reviews  
vi) critique of the GCA literature, based on the thesis work 
i)   The NN-LR prediction model with its favorable decision curve analysis and geographic 
external validation has direct, immediate clinical application for the triage of patients with 
suspected GCA.  Unlike clinical intuition, which may be prone to bias, the prediction model 
incorporates ten variables including symptoms, signs, and blood tests to provide an objective 
pretest probability for GCA.  The pretest probability is helpful for shared decision-making 
with patients suspected to have GCA, and in such algorithms as the one used in the British 
Society of Rheumatology Guidelines for GCA (Mackie et al., 2020)  [see Figure 19 below].  
The prediction model can decrease the number of TABx performed on low risk subjects with a 
tripartite benefit.  Fewer patients will undergo a low yield invasive procedure.  Surgeons will 
have time to perform more productive clinical activities, and medical funding can be 
redirected for greater utility.                                                                                                            
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 Since patients and some clinicians may not comprehend the statistical details of the 
NN-LR article a plain language summary and explanatory video are available online, along 
with the link to the calculator.  (The underlined elements in the previous sentence are clickable 
links.) 
ii)     The research has been presented at international, national and local venues.  The logistic 
regression and nomogram were introduced at the 2018 North American Neuro-ophthalmology 
Society Meeting (Torun et al., 2018).  The clinical application of the GCA prediction models 
was presented at two recent Canadian Ophthalmological Society (COS) Meetings, (Ing et al., 
2017; Ing, 2019a)  and a recording of the NN-LR presentation is online.  The research 
methodology of the GCA prediction models was discussed at the University of Toronto 
Ophthalmology Research Day in fall 2017 and fall 2018.  The University of Toronto was 
ranked 21st in the World University Rankings in 2019 (Times Higher Education, 2019).   
iii)     Professional networks and teaching opportunities beget the potential to disseminate 
scholarly work and influence present and future generations of physicians.  The co-authors of 
the NN-LR paper were from the eight dominant medical schools in Canada, along with 
contributors from Harvard, Johns Hopkins, and the Mayo Clinic.  The co-authors were enlisted 
through my membership in nine ophthalmic speciality organizations.  The internet lines of 
these professional organizations facilitated the exchange of opinions on the prediction models 
and epidemiology of GCA as well as practice preferences in the work-up of GCA.   
     The University of Toronto is Canada’s largest medical school with numerous opportunities 
to interact with fellows, residents, and medical students and to participate in post-graduate 
medical education forums.  Residents and medical students participated in the data collection 
of three of the thesis publications and presented two of them as posters at the June 2018 
Canadian Ophthalmologic Society meeting (Lahaie Luna, Ing and ten Hove, 2018; Wang, 
Benard-Seguin and Ing, 2018). 
     The influence of the GCA research is supported by nominations for the 2020 Bressler Prize 
in Vision Science, and the 2020 Harvard Chan Alumni Award of Merit.8   
 
8 The Bressler award is an annual $54,000 prize offered by the Lighthouse Guild in New York, NY to a “clinician or scientist whose 
leadership, research and service have led to substantive advancements in the understanding of vision loss, treatment of eye disease, or the 
rehabilitation of people with vision loss” (Lighthouse Guild, 2019).  My nomination was supported by Dr. Neil Miller, the Frank B. Walsh 
Professor of Neuro-Ophthalmology and Professor of Ophthalmology, Neurology & Neurosurgery at the Johns Hopkins University School of 
Medicine in Baltimore, Maryland.  The Harvard Chan Alumni Award of Merit was put forth by my MPH classmates. 
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iv)     The topic of GCA has an eminent impact in the medical literature.  In August 2019, 
GCA was assigned a SciVal Topic Prominence percentile of 97.060, on Scopus, which 
indicates a high “momentum, movement or visibility of a collection of documents with a 
common intellectual interest” (Elsevier, 2019).  
     My Scopus h-index is 11.  All the major thesis works were published since February 2019.  
The Scopus field-weighted citation impact (FWCI) 9 was available for six of the thesis 
publications in July 2019, with a mean of 2.57+/-1.56 and median 2.43.  A FWCI value 
greater than 1.00 means that the document is more cited than expected according to the 
average.  For example, a score of 1.44 means that the outputs have been cited 44% more times 
than expected (USC Australia, 2018).        
 
 
 
Table 8. Article Citations and Journal Metrics as of July 2019 
Article Citations in the 
Literature  
Google 
Scholar/Scopus 
Field-
Weighted 
Citation 
Impact (July 
2019) 
Total Article 
View Metrics 
(Dove Press, 
July 2019) 
Neural network and logistic regression 
diagnostic prediction models for giant cell 
arteritis: development and validation.  Ing 
EB, Miller NR, Nguyen A et al  Clin 
Ophthalmol. 2019 Feb 21;13:421-430 
- - 4,703 
The incidence of giant cell arteritis in 
Ontario, Canada. Ing EB, Lahaie Luna G et 
al.  Can J Ophthalmol. 2019;54(1):119-124 
2/1 4.85  
Does herpes zoster predispose to giant cell 
arteritis: a geo-epidemiologic study. Ing 
EB, Ing R, Liu X, Zhang A, Torun N, Sey 
M, Pagnoux C. 
Clin Ophthalmol. 2018 Jan 11;12:113-118. 
6/4 3.08 5,729 
Systematic Review of the Yield of 
Temporal Artery Biopsy for Suspected 
Giant Cell Arteritis. Ing EB, Wang DN, 
Kirubarajan A et al. Neuroophthalmology. 
2018 Jun 19;43(1):18-25. 
1/1 2.43  
 
9 “The Field-Weighted Citation Impact shows how well cited this document is when compared to similar documents. It accounts for:  the year 
of publication, document type, and disciplines associated with its source. The FWCI is the ratio of the document's citations to the average 
number of citations received by all similar documents over a three-year window. Each discipline makes an equal contribution to the metric, 
which eliminates differences in researcher citation behavior” (Scopus, 2015) 
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The Use of a Nomogram to Visually 
Interpret a Logistic Regression Prediction 
Model for Giant Cell Arteritis.  Ing EB, 
Ing R.  Neuroophthalmology. 2018 Feb 
5;42(5):284-286 
3/2 1.57  
Bloodwork statistical prediction model for 
giant cell arteritis.  Ing E., Intern Med J. 
2018 May;48(5):607-608 
2/1 1.24  
Multivariable prediction model for 
suspected giant cell arteritis: development 
and validation. Ing EB, Lahaie Luna G, 
Toren A, et al Clin Ophthalmol. 2017 Nov 
22;11:2031-2042 
16/12 4.20 6,955 
New oral anticoagulants and oculoplastic 
surgery. Ing E, Douketis J, Can J Ophthalmol, 
2014: 49(2):123-7. 
13/7   
Polyangiitis overlap syndrome with 
granulomatosis with polyangiitis 
(Wegener's) and giant cell arteritis. 
Ong Tone S, Godra A, Ing E. 
Can J Ophthalmol. 2013 Feb;48(1):e6-8 
3/4 0.63  
Systemic amyloidosis with temporal artery 
involvement mimicking temporal arteritis. 
Ing EB, Woolf IZ, Younge BR, Bjornsson 
J, Leavitt JA. Ophthalmic Surg Lasers. 
1997 Apr;28(4):328-31 
18/17 -  
 
Table 9. Journal Rank of Ophthalmology Publications 
Journal 2018 Scimago Journal Rank  
Current Opinion in Ophthalmology 1.299 (Q1) 
Clinical Ophthalmology 0.994 (Q1) 
Journal of Neuro-ophthalmology 0.625 (Q2) 
Canadian J Ophthalmology 0.578 (Q2) 
Neuro-ophthalmology 0.286 (Q3) 
 
v)     The journal, Current Opinion in Ophthalmology annually reviews the topic of GCA by 
inviting an author to comment on literature from the previous year.  I was invited to be the 
lead author of the fall 2019 review of GCA, on the topic “Advances in the Diagnosis of Giant 
Cell Arteritis” and discussed many of the thesis publications.   Current Opinion in 
Ophthalmology is one of the top quartile journals in the field of ophthalmology with an impact 
factor of 2.824, and SciMago Rank 1.299. 
      I was invited to review three articles on GCA by the Canadian Journal of Ophthalmology 
in February 2017 (Weis et al., 2017), BMC Geriatrics in May 2019 (González-Gay et al., 
2019), and the Journal of Headache and Pain in September 2019.  The article by Weis et al 
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did not have internal validation, and I was able to provide the authors with the Stata code to 
complete a cross validation.   The last article I reviewed was accepted in March 2020, and 
concerned the European Headache Federation guidelines for neurologists managing GCA.  My 
comments are listed in Appendix I.    
vi)     I published five critiques of the GCA literature, which supports the ability for 
“independent critical power”.  Three of the letters commented on alternative statistical models 
for GCA.   
     The critique of Oh et al’s article (Oh, Wong, Andrici, et al., 2018) commented that logistic 
regression requires complete case analysis, and that reported sample sizes should not be 
inflated when there is missing data.  Also, the concern for multicollinearity on multivariate 
analysis was expressed given the multiple lymphocyte ratio analyses (Adamczak, 2017; Ing, 
2018).       
     The article concerning Laskou et al’s  GCA probability score (Laskou et al., 2019) 
expressed the concern about overfitting because their 17-predictor variable model was 
developed from only 23 cases of GCA and a total dataset of 122 subjects.  Furthermore, the 
assignment of the same arbitrary integer values to predictors of varying importance was 
questioned. 
     Moraña et al (Moraña et al., 2019) asserted that prediction models may decrease the need 
for TABx but suggested the use of González-López’s logistic regression prediction model that 
requires the input of the TABx length.  My Letter to the Editor emphasized that logistic 
regression requires complete-case analysis without missing data.  As such the NN-LR models 
that calculate GCA risk prior to the TABx result are a more rational alternative (Ing, 2019b). 
     My fourth Letter to the Editor concerned Ross et al’s case-control study of 27 GCA 
subjects with diplopia, (Ross et al., 2019) to estimate the differentiating features of diplopia in 
patients with and without GCA.  The major disadvantages of case-control studies include 
incomplete control of extraneous variables and bias in selecting an appropriate matched 
comparison group (Schulz and Grimes, 2002).  Given the size and design of our NN-LR 
retrospective cohort study, we were able to add the perspective of 40 additional patients with 
BPGCA and diplopia with a more accurate comparison of the features that differentiated them 
from the diplopia subjects without BPGCA.  Although our patients with diplopia and GCA 
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had statistically significant greater age, jaw claudication, vision loss, ESR, CRP and platelet 
levels than patients with diplopia and a negative TABx, diplopia was not a statistically 
significant predictor for GCA on univariate or multivariable analysis.  In my strabismus 
practice, the vast majority of patients presenting with diplopia do not have GCA.  Also, 
diplopia may have been a weak predictor for GCA because in our study 20% of our subjects 
overall with BPGCA had vision loss; patients who are blind in one or both eyes are less prone 
to binocular diplopia.   
     The fifth letter to the editor addressed Lyons et al “new era” in GCA (Lyons et al., 2019) 
which suggested that TABx was no longer the gold standard for the diagnosis of GCA.  
However at least one meta-analysis (Rubenstein et al., 2019) and another Bayesian analysis 
(Niederkohr and Levin, 2007) support the higher sensitivity and specificity of TABx relative 
to ultrasound.  The possibility of false-positive ultrasound was mentioned and advantages of 
tissue diagnosis for diseases that mimic the symptoms and signs of GCA, and the high initial 
cost of point-of-care ultrasound equipment were discussed.   My comment on the suboptimal 
TABx from the TABUL study (7% missed biopsies, and 43% TABx less than 1 cm) was 
acknowledged by the UK authors who responded, “Sadly, this reflects routine care within the 
normal NHS [National Health Service] practice” (Mollan et al., 2019).
     Lastly, the recently published British Society of Rheumatology (BSR) guideline (Mackie et 
al., 2020) recommended  “Patients with suspected GCA should have a confirmatory diagnostic 
test. This could be either a temporal artery biopsy at least 1cm in length, or an ultrasound of 
the temporal and axillary arteries, or both.”  I agree with this recommendation. 
     Figure 1 of the 2020 BSR guideline for suspected cranial GCA (designated Figure 19 in 
this thesis) advocates the use of clinician judgment to triage patients into low, medium and 
high-risk groups followed by ultrasound.  The BSR further stated that “various clinical 
prediction rules have been proposed to assist clinicians in the estimation of the probability of 
GCA; the performance of a clinical prediction rule developed in another setting should ideally 
be checked using local audit data prior to adopting into local clinical practice.”   Outwardly 
this seems prudent, but the bias in using clinician judgment to risk stratify GCA more than 
likely exceeds any potential bias from a multi-centre, prediction model with external 
validation, such as the NN-LR because:   
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Figure 19. British Society of Rheumatology (BSR) 2020 algorithm for suspected giant cell 
arteritis 
                            
 
i) Expertise in vascular ultrasound is highly operator dependent (Landau, Savino and 
Gruber, 2013). False-positive ultrasound tests can occur with atherosclerosis (De 
Miguel et al., 2018) and other conditions (Fernández et al., 2019) between 4.3-10% 
of cases.  
ii) Clinical judgment is usually not as accurate as a prediction algorithm (Ayres, 2007; 
The Medical Futurist, 2016; Parikh, 2018). Humans cannot accurately, 
simultaneously weight multiple variables, especially when there are non-linear 
relationships.  No matter how experienced clinicians believe they are, humans are 
prone to cognitive errors and bias.  
     I suggested to the BSR that a more judicious position statement would be to caution against 
the use of prediction rules derived from small numbers of patients, without external validation, 
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or non-compliance with the TRIPOD guidelines.  The NN-LR rule was developed from the 
data of multiple centres in North America, and the external validation set included patients 
from Switzerland. 
     Figure 20 shows the congruency of the BSR guidelines and NN-LR in the regions of the 
orange dashed outlines.  A disadvantage of the BSR risk category designations is that they are 
arbitrary.  Given the catastrophe of possible bilateral vision loss from undiagnosed GCA some 
may feel the upper limit of “low risk” for GCA should be less than 20%.  To help physicians 
calibrate their numeric clinical judgments on risk, a table of risk scores generated from the 
NN-LR model for hypothetical GCA clinical scenarios is provided in Appendix F. 
       The BSR guideline to avoid TABx in patients at high risk for GCA given a positive 
ultrasound (pink question mark at the bottom left of Figure 20) is controversial.  If the BSR 
persists on the exclusive use of ultrasound for this category of patients it would be safer if 
bilateral, circumferential US haloes of thickness 0.7 mm or greater (Pouncey et al., 2018) 
were required to forego TABx.  Ideally all patients consigned to long term glucocorticoids 
should have biopsy confirmation of disease due to the potential risks of glucocorticoids.  
Ultrasound can be misleading (De Miguel et al., 2018; Fernández et al., 2019).  The pathology 
from TABx may occasionally reveal a myriad of alternative diagnoses including syphilis, 
sarcoid and amyloidosis (see Section 2.2.1 page 35).   
 
Figure 20. Comparison of Neural Network-Logistic Regression Calculator with the British 
Society of Rheumatology (BSR) 2020 Guidelines for GCA 
GCA  Opinion on Guidelines & Critical Reflections 
 
84 
 
 
     In summary, the impact of the thesis work on GCA is evidenced by the publications, 
presentations, critiques of the GCA literature/guidelines, and nomination for the Bressler Prize 
in Vision Research.  The NN-LR model confirms the importance of platelets over ESR and 
CRP, and the need to include platelets in the core data set for GCA treatment and research, a 
point that was not appreciated in Table 1 of the 2018 EULAR recommendations (Ehlers et al., 
2019).  Most importantly the NN-LR model shifts the paradigm of clinical diagnosis from 
reliance on clinical intuition or subjective estimations of probability, (Mackie et al., 2020) to 
clinical judgment assisted by an objective, externally validated risk stratification.   
 
 
Chapter 6. CRITICAL REFLECTIONS AND FUTURE WORK  
     Critical reflections on the research work included:  i) the need to decrease the barriers to 
de-identified health care data, and the importance of electronic health records. ii) the 
obligation for robust, independent assessment of peer-reviewed literature iii) the perception of 
the GCA literature by different medical specialties may be biased and iv)  the resistance of 
clinicians to using computerized algorithms. 
i)   Although a doctoral degree emphasizes independent and scholarly work, collaboration is 
required especially for data acquisition in the modern era. The most difficult aspects of the 
research were the delay in ethics board approval from collaborating institutions, although the 
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data were de-identified. “Dissatisfaction with the [ethics board] review process, particularly 
the time interval from submission to decision, is common within the research community” 
(Page and Nyeboer, 2017).  The protection of patient privacy, patient safety and autonomy are 
paramount.  Paradoxically, the convoluted access to non-sensitive, de-identified retrospective 
data to qualified and vetted health care researchers is a barrier to safeguarding and improving 
the health care of patients.  To improve future research accessibility, citizens could be given 
the option to post their de-identified health care data for research, much like the presently 
available organ and tissue donor registration programs (Government of Ontario Health and 
Wellness, 2019).  I suggested that the provincial and federal health agencies establish a 
publicly available database for research, (see Appendix G) that would be free of charge to 
researchers.  This database could dovetail with existing patient-oriented research organizations 
such as the Strategy for Patient-Oriented Research in Canada (Aubin, Hebert and Eurich, 
2019). 
     The adaptations required to carry out the incidence of GCA in Ontario study were complex. 
Despite Ontario, Canada having a universal health care system, it has no mechanism to 
enumerate the number of positive TABx performed in its pathology labs.  With the increasing 
use of electronic medical records, future researchers will hopefully have better access to such 
data.   
ii)  When evaluating the performance of TABx as a test, competent execution of the biopsy 
must be ensured with procurement of an adequate length specimen, and appropriate 
interpretation by the pathologist.  This sine qua non must be considered even when 
interpreting influential, peer-reviewed publications such as TABUL (Luqmani et al., 2016). 
Critical deficiencies in the TABx technique were not listed in the abstract of the TABUL 
study.  TABUL is 237-page report, and one must delve into the document to discover that 7% 
of the attempts at TABx were missed, and when an arterial specimen was obtained 43% were 
shorter than the 1 centimetre length suggested by the British Society of Rheumatology 
guidelines.  The ultrasounds in TABUL were performed at a high standard, but the TABx 
were subpar; any claims of the comparative diagnostic accuracy of the two techniques are 
biased (Rubenstein et al., 2019).  Articles that repeatedly quote the TABUL study as 
justification for bypassing TABx (Lyons et al., 2019) are unsettling, especially given the 
possibility of false-positive ultrasounds and glucocorticoids side effects.   
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     Notwithstanding, the increased use of imaging methods to diagnose GCA in the future is 
anticipated.  This is only partly due to the diffusion of innovation (Rogers, 1983) as ultrasound 
for the diagnosis of GCA has been described at least since 1981 (Dany et al., 1981).   Rather, 
the use of imaging will expand if it becomes more difficult to obtain timely and properly 
performed TABx (Mollan et al., 2019).  The number of TABx performed annually in Ontario, 
Canada may be declining, (Micieli, Micieli and Margolin, 2015)  at least in part because they 
are not well remunerated throughout North America.  In my locale surgeons often decline 
referrals to perform this procedure, or are not provided sufficient hospital resources to perform 
the procedure in a timely fashion.   
iii)  The neuro-ophthalmology and rheumatology communities may perceive the GCA literature 
from different perspectives.  Most ophthalmologists see patients with the cranial arteritis variant 
of GCA, who require high dose glucocorticoids to avert vision loss.  However, internal medicine 
specialists are more frequently referred patients with polymyalgia rheumatica, or the limb 
claudication and pyrexia of unknown origin variants of GCA, that may respond to lower dose 
glucocorticoids (Fraser et al., 2008).  After publication of the P-LR article, a reviewer 
unknowingly opined that “the model authors are ophthalmologists and thus are focusing on 
patients who present with cranial symptoms” (Holliman, 2018).  The reviewer did not realize 
we had rheumatology and neurology coauthors, that the ophthalmic surgeons in the study were 
the primary biopsy service for many of the rheumatologists at their respective institutions, and 
that hospital chart reviews incorporated all patients who underwent TABx regardless of which 
service performed the biopsy.  Furthermore, all the non-biopsy 1990 American College of 
Rheumatology classification criteria for GCA were incorporated in the P-LR model.   Although 
the referral service was not indicated for every patient in the database of our publications, where 
the information was available, 52% of the P-LR patients were referred by rheumatologists, 
internal medicine specialists or primary care physicians.  In the subsequent NN-LR model 
46.8% of the patients were referred by non-ophthalmologists. This bolsters the generalizability 
of our P-LR and NN-LR models. 
iv) Resistance to the use of actuarial methods by “expert specialists” has existed since Paul 
Meehl’s “disturbing little book” in the 1950s (Meehl, 1954).  As computerized algorithms 
improve, so must our willingness to adopt them.  Robert Pearl, M.D. states, “the biggest barrier 
to artificial intelligence in medicine …. is a medical culture that values doctor intuition over 
evidence-based solutions.  Physicians cling to their independence and hate being told what to 
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do.” (Pearl, 2018)  No prediction models are perfect and artificial intelligence (AI) will not 
replace physicians, but AI can make doctors better (Parikh, 2018).  The role of prediction 
algorithms is to objectively guide clinical judgment.   
 
     Areas for future research endeavour include:   a)  Optimization of the diagnostic yield of 
TABx and quality control in the interpretation of TABx  b) Optimization of the NN-LR model  
and c) the incorporation of imaging results with the NN-LR model to determine the post-test 
probability of GCA. 
a) The yield of TABx may increase with standardization of the pathology reading 
process and special stains.  Towards this end we will need to survey Canadian 
pathologists to ascertain the average length of the specimen they receive, the 
percentage of bilateral specimens, the number of sections they initially perform, if the 
artery is initially sectioned entirely, the number of sections that are initially examined, 
and whether or not further sections or special stains are ordered if the initial 
pathology appears unrevealing. The survey has been developed and soon to be 
launched is at https://s.surveyplanet.com/lYLQOF7uv  Having a centralized quality- 
control consensus centre for TABx interpretation would also be an asset if funds 
permitted. 
b)      The thesis prediction models could be bolstered by larger sample sizes, further external 
validations, the prospective collection of information and a statistical analysis to account for 
multiplicity errors.  The response categories of the presently binary variables could be 
increased.  For example, for jaw claudication (JC), three response levels could be used:  
definitely not JC, possible JC, and highly likely JC.  Additional predictors might include neck 
pain, body mass index, and smoking.  Practical reasons were provided to exclude polymyalgia 
rheumatica as a predictor (Section 4.1.1, page 56) but formal testing would help settle any 
controversy.  With greater study numbers more hidden layers could be added to the neural 
network, to reduce overfitting of the data.  The performance of the NN-LR prediction models 
could be examined in conjunction with dynamic contour tonometry (Ing, Pagnoux, et al., 
2018), wide-field swept-source OCT angiography (Tran et al., 2018), ultrasound, MRI or 
genetic tests such as HLA-DRB1*04 (Carmona, González-Gay and Martín, 2014).  A 
Bayesian updating approach might improve the spatial and temporal transferability of the 
prediction models (Xu et al., 2014). 
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     The use of a false discovery rate (FDR) instead of traditional p-values to analyze the 
statistical models would decrease the possibility of errors from multiple testing.  10  The FDR 
is the expected proportion of false positives among all positives, or the expected proportion of 
false predictions divided by the total number of predictions, and has more power than the 
conservative Bonferroni method (Jafari and Ansari-Pour, 2019). 
c)      To determine the post-test probability of GCA following ultrasound or MRI, the NN-LR 
pre-test probability could be combined with the sensitivity and specificity values from recent 
meta-analyses of imaging (Duftner et al., 2018; Rinagel et al., 2019).  Likelihood ratios are 
derived by Bayes Theorem as outlined in Appendix J  (https://preview.tinyurl.com/y6hxlbl9) . 
     The penultimate research development in the diagnosis of GCA, which is beyond the scope 
of this thesis, would be the development of a highly specific and sensitive serology and 
genetic markers to diagnose or predict GCA without the need for TABx or ultrasound. 
 
Chapter 7. CONCLUSIONS 
     GCA is a potentially vision-threatening emergency that also may cause aortitis, stroke or 
occasionally death.  GCA is the most common primary vasculitis in the elderly, and a 
burgeoning public health concern in our ageing population. 
     A summary of the knowledge contributions from the published works include:  
1) The incidence of biopsy-proven GCA in Ontario, Canada is 4.9 per 100,000 
individuals over 50 years of age.    The incidence figure is useful for epidemiologic 
and public health planning purposes. 
2) Ecologic analysis of the incidence rates of herpes zoster versus GCA from different 
countries showed an inverse relationship and suggests that zoster is unlikely to be a 
strong immunopathogenic trigger for the development of GCA. 
3) Temporal artery biopsy (TABx) remains the current reference standard confirmatory 
test for GCA.  Perioperative anticoagulant and local anaesthetic issues should be 
considered prior to TABx.  Although Doppler ultrasound is becoming increasingly 
utilized, false-positive imaging results are worrisome.  Our 2019 survey showed that 
over 90% of North American ophthalmologists and rheumatologists prefer TABx over 
 
10   Using JMP Pro’s false discovery rate algorithm, the ESR, gender and diplopia are not statistically significant 
predictors for biopsy-proven GCA.  The calculations are in the appendix of the NN-LR article.  
https://docs.google.com/document/d/1kHVMxFmFDE-1UdSGMc65juD_h5Vd7mQCvAGR3s3bPJ4/edit 
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ultrasound whereas 74% of European neuro-ophthalmologists prefer TABx over 
ultrasound.  
4) GCA can have diverse systemic and ocular manifestations and can be mimicked by 
other diseases including amyloidosis and overlap with granulomatosis with 
polyangiitis.  Although the result of TABx may be negative for GCA, the biopsy 
occasionally may disclose pathologic confirmation of other diseases that simulate the 
presentation of GCA. 
5) Systematic review for the positive yield (utility rate) of TABx, showed marked 
heterogeneity with a median yield of 25% and interquartile range 0.17 to 0.34 (Ing, 
Wang, et al., 2018).  Centres with a utility rate for TABx below 17% should determine 
if they are performing too many biopsies, obtaining inadequate length biopsies, or 
perhaps incorrectly processing biopsies.  The diagnostic prediction models may 
improve the positive yield of TABx. 
6) Statistical prediction models objectively weight the multiple risk factors for GCA and 
usually outperform clinical “intuition”.  Resistance to the use of prediction algorithms 
in medicine does not seem uncommon.  In the age of artificial intelligence, medical 
societies should test published diagnostic prediction models, and incorporate the best 
models into their societal guidelines.  Diagnostic prediction rules are not infallible and 
are not meant to replace clinical judgment, but to enhance it.   
7) Prediction models for GCA may decrease the number of TABx performed on low-risk 
patients, as well as the number of unnecessary glucocorticoid initiations.  In our NN-
LR prediction model a risk score cut-off of approximately 7% allowed for 99% 
sensitivity, which can be used as a triage criterion.  The publications provide the first 
online calculators to determine the risk of GCA prior to TABx. 
8) The Kattan nomogram and the online risk calculator https://goo.gl/THCnuU 
allow easy access to the output of the GCA risk models.  A Kattan nomogram can 
visually illustrate the risk contribution of the predictor variables used in the logistic 
regression prediction models for GCA.  The nomogram allows clinicians, including 
those without statistical expertise to comprehend the relative contribution of 
continuous versus binary variables, in addition to the odds ratios of logistic regression. 
9) The 1990 American College of Rheumatology (ACR) classification criteria for GCA 
(for update in late 2019) were not intended for diagnosis, and can miss cases of GCA.  
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The primary 10-factor multivariable logistic regression (LR) model with area under the 
receiving operating characteristic curve (AUROC) = 0.82 outperformed the pre-biopsy 
1990 ACR criteria with AUROC = 0.63.    
10) In our final prediction models (n=1,201), with age and bloodwork maintained as 
continuous variables, multivariable logistic regression showed that age, platelets, jaw 
claudication, vision loss, log transforms of the C-reactive protein and erythrocyte 
sedimentation rate, headache, and clinical temporal artery abnormality were 
statistically significant predictors of a positive TABx (p ≤0.05).  Age, platelets, vision 
loss and jaw claudication were stronger predictors for GCA than ESR and CRP, 
headache and scalp tenderness.   
11)  Acute phase reactants are serum proteins that increase in concentration with 
inflammation or tissue injury and include platelets, C-reactive protein and, the 
erythrocyte sedimentation rate.  The dominance of platelets as a predictor of GCA over 
CRP and ESR is not well appreciated, in part because most GCA studies dichotomize 
bloodwork results rather than maintaining them as continuous variables.  The mean / 
median platelet level for the GCA group was 372 (+/-143 x109L) / 342 x 109/L, well 
below the 400-450 x 109/L thrombocytosis cut-off used in the literature (Foroozan et 
al., 2002).  The maintenance of predictors such as age and acute phase reactants as 
continuous variables will optimize statistical power.    If alternative risk models persist 
in dichotomizing platelet levels, consideration should be given to lowering the platelet 
cut-off level for GCA to 350 x 109/L rather than the traditional 400 x 109/L. 
12)  Normal serology (the combination of ESR < 50 mm/hour, plus CRP and platelets at or 
below their upper limit of normal) was present in 10% of the patients with biopsy-
proven GCA.  Twenty per cent of these seronegative patients had healed arteritis. 
13)  On multivariable analysis gender and diplopia were not statistically significant 
predictors for GCA.  Seventy one percent of our patients with GCA were women, and 
this female preponderance is consistent in the GCA literature.  However, sex was not a 
statistically significant predictor for a positive TABx in our studies and other LR 
studies.   This is likely explained by the increased longevity of women versus men in 
population demographics.  Patients with vision loss in one or both eyes usually do not 
have binocular diplopia.   Twenty per cent of our GCA patients experienced vision 
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loss, and this may explain why diplopia was not a statistically significant predictor for 
GCA on multivariable analysis. 
14)  There is overlap in the presenting features of patients with and without biopsy-proven 
GCA, and misclassification remains a concern for all prediction models. The neural 
network model for GCA had fewer false negatives than its logistic regression 
counterpart, but a support vector machine statistical model was equivalent to logistic 
regression.  Decision curve analysis affirms the utility of our neural network and 
logistic regression diagnostic prediction algorithms. 
15)  In the future prediction models might be combined with ocular blood flow tests, 
imaging studies or genetic tests to increase diagnostic accuracy and further avert vision 
loss, TABx and the unnecessary initiation of glucocorticoids. 
 
     In summary, GCA remains a prime emergency in ophthalmology and medicine.  The thesis 
comes full circle as the malapropism in the 1989 New Zealand article in the preface (Figure 1) 
recapitulates with the identical misprint in a 2018 GCA publication from Spain (Figure 21, 
(González et al., 2018)).  These two reports not only emphasize that GCA remains a global 
problem but remind us that physicians and patients continue to seek alternatives to TABx like 
a “temporary” artery biopsy or ultrasound.  
     The thesis publications on diagnostic prediction rules with online risk calculator, the yield 
of temporal artery biopsy, the test preferences for the confirmation of GCA, the incidence of 
GCA in Canada, the limited relationship between herpes zoster and GCA, and the literature 
critiques provide new perspectives on the characteristics and management of GCA.  In 
particular, the prediction models may help decrease the number of TABx performed in low-
risk subjects. 
 
Figure 21. Malapropism:  "Temporary" artery biopsy and ultrasound study from Spain. 
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This Spanish publication echoes the malapropism from the New Zealand article (Figure 1) 
written 30 years prior.  González-Porto et al found the sensitivity and specificity of the 
ultrasound hypoechoic halo were both 30% less than temporal artery biopsy.  Together the 
two “temporary” artery biopsy articles mirror the time-line of my medical career and 
emphasize that GCA remains a serious global concern and that we are still searching for a 
reliable but less-invasive procedure to confirm the diagnosis of GCA 30 years later  (González 
et al., 2018).  https://www.ncbi.nlm.nih.gov/pubmed/30318270 
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APPENDIX  
Appendix A.  Over-the-counter medications with potential anticoagulant effect, from Table 3 
in publication: (Ing and Douketis, 2014) 
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Appendix B.  The Incidence of GCA in different countries from Table 1 (Ing, Lahaie Luna, et 
al., 2019) 
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Appendix C, Research Degree Declaration Form RD12A 
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Appendix D:   Practice Preference Survey Temporal artery biopsy versus Ultrasound 
 
Appendix D1:  Survey Questions  
 
Appendix D2:  Estimation of Survey Response Rate 
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Appendix D3:  Calculation of Survey 95% Confidence Intervals 
Calculation of survey 95% confidence intervals was done using the online tool:  
https://www.surveysystem.com/sscalc.htm 
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Appendix D4:   Statistical Tests for Regional Differences in O&N Preference for TABx 
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Appendix D5:   Statistical Tests for Specialty Differences in Preference for TABx 
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Appendix E.   Correlation and Linear Regression of the Incidence Rates of GCA versus 
Herpes Zoster, Table 2 from the publication:  (Ing, Ing, et al., 2018) 
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Appendix F.  Hypothetical Clinical Scenarios showing the Risk Score Predictions of the 
Neural Network and Logistic Regression Models for High, Medium and Low risk GCA 
 
Legend for Appendix F 
LR = logistic regression;   NN = neural network 
M = male; F = female 
HA - = no headache; HA+ = headache present 
TAnl = no temporal artery abnormality; TAabn = temporal artery abnormality 
JC- =no jaw claudication; JC+ = jaw claudication present 
Dip- = no diplopia; Dip+ = diplopia 
Plat = platelets x 10^9/L 
ESR = erythrocyte sedimentation rate mm/ hr 
CRP / ULN = C-reactive protein divided by upper limit of normal for each lab 
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Appendix G.  Citizen Research Participant Registry 
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Appendix H.  TRIPOD Checklist   downloaded from the EQUATOR network.  
https://www.equator-network.org/reporting-guidelines/tripod-statement/ 
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Appendix I.  GCA Article Reviews  
 
Review for Canadian Journal of Ophthalmology in February 2017 (Weis et al., 2017),  
 
Review for BMC Geriatrics in May 2019 (González-Gay et al., 2019) 
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Review for Journal of Headache and Pain in September 2019 (article accepted March 2020) 
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ESR, CRP and platelets are all acute phase reactants. The platelet level must be specifically mentioned as 
it is the strongest bloodwork predictor for GCA. Reference 25 used by the authors graphically shows the 
importance of platelets in comparison to ESR and CRP. Pubmed search of the recent GCA literature will 
reveal numerous other references indicate the importance of a "relative thrombocytosis" for GCA. 
Because the odds ratio of platelets seems small in papers such as Clin Ophthalmol, 2019, on examination 
of an odds ratio summary table, the average reader may not realize the importance of platelets as a 
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examining risk models as an adjunct to "clinical intuition". Clinicians should refrain from dichotomizing 
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temporal artery biopsy patients, the average platelet value of the positive biopsy group was 372 x 109/L 
compared to 283 x 109/L in the negative biopsy group. However, clinicians tend to use a platelet cut-off 
of 400 x 109/L for the diagnosis of GCA. Once again, the value of an objective risk calculator is shown. 
The same thinking applies to age, which has an exponential risk for GCA. 
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Dr. Luqmani is one of the authors in this headache paper as well as the lead author of the TABUL study 
which is an excellent ultrasound paper.  However, with all due respect in the TABUL study, the very low 
quality of the temporal artery biopsies is not a fair comparison with the very high quality ultrasound 
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performance. In 7.3% of the TABUL study subjects, instead of a temporal artery specimen, structures 
such as veins, fat, muscle or nerve were harvested. This is an unacceptable failure rate. Of the temporal 
artery specimens obtained in the TABUL study, a remarkable 43% were less than 1 cm in length, which is 
also glaringly substandard (see British Society of Rheumatology guidelines). Unfortunately, these 
important details were not mentioned in the abstract of the TABUL study.  
If the EHF GCA mentions the TABUL study, it should emphasize the deficiencies of the temporal artery 
biopsies in the TABUL study, so as not to propagate misinformation about temporal artery biopsy. 
Please note that as a reviewer I have no financial interests whatsoever in performing temporal artery 
biopsy, or suggesting that temporal artery biopsy be continued over ultrasound. However, having only 
TABUL abstract when it was initially published, I was completely misled regarding its conclusions until I 
delved in to the 238 page pdf document. 
 
Furthermore, the authors should comment on this meta-analysis which shows poor sensitivity and 
specificity of the hypoechoic halo compared to temporal artery biopsy. 
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Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic 
review and meta-analysis of the literature. 
Rinagel M1, Chatelus E1, Jousse-Joulin S2, Sibilia J1, Gottenberg JE1, Chasset F3, Arnaud L4.  
Based on a total of 20 studies, the sensitivity and specificity of hypoechoic halo compared to positive 
temporal artery biopsy were respectively of 68% (95% CI: 57-78) and 81% (95%CI: 75-86).  
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The EULAR recommendations (Dejaco, et al., 2018) stress that CDUS must be properly performed by 
experienced ultrasonographers. The possibility of false positive ultrasound results should be clearly stated 
with references. 
Dejaco, C. et al., 2018. EULAR recommendations for the use of imaging in large vessel vasculitis in 
clinical practice. Ann Rheum Dis, 77(5), pp. 636-643. 
 
Incidentally, a 2019 practice pattern survey, for publication in October 2019, found that 74% of European 
neuro-ophthalmologists and over 90% of North American neuro-ophthalmologists prefer temporal artery 
biopsy over ultrasound for the work-up of giant cell arteritis. 
 
Page 13  
When ophthalmic symptoms are present, glucocorticoid treatment should be initiated and ophthalmic 
consultation should be obtained. 
 
Treatment: Provide the reference for 40 mg oral prednisone treatment, which I presume is in the 
rheumatology literature. The ophthalmology literature suggest that the minimum vision protective 
prophylactic dose for suspected GCA is 1 mg/kg (i.e. closer to 60 mg) oral prednisone, with higher dose 
i.v. glucocorticoid for patients who already have vision symptoms. 
 
Page 15 Provide a reference for the proton pump inhibitor statement given Jones' article 
Jones MG, Tsega S, Cho HJ. Inappropriate Prescription of Proton Pump Inhibitors in the Setting of Steroid 
Use: A Teachable Moment. JAMA Intern Med. 2016;176(5):594-595. 
doi:10.1001/jamainternmed.2016.0603 
The literature suggests no benefit from PPI prophylaxis in patients taking systemic corticosteroids without 
concomitant NSAID use. Furthermore, PPIs have been linked to numerous adverse events. Studies5 show 
a 2- to 3-fold increase in renal disease such as acute kidney injury in PPI users compared with nonusers 
and a 74% higher risk of developing Clostridium difficile infection. In addition to these adverse effects, 
the case described herein highlights the dermatologic drug reactions that may stem from PPI use.  
 
 
Appendix J.  The Post-test probability of GCA after Imaging or Negative Biopsy 
Abstract submitted to the Canadian Ophthalmological Society, Nov 4, 2019. 
https://preview.tinyurl.com/y6hxlbl9 
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Pre-Test Probability = result from the NN-LR calculator = PNN-LR 
Pre-Test Odds = PNN-LR/(1 – PNN-LR)     
LR+ = sensitivity / (1-specificity) 
LR- = (1-sensitivity) / specificity 
Post-Test Odds = Pre-Test Odds * Likelihood ratio 
Post-Test Probability = Post-Test Odds/(1 + Post-Test Odds) 
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